Page last updated: 2024-08-21

quinazolines and Neoplasm Metastasis

quinazolines has been researched along with Neoplasm Metastasis in 450 studies

Research

Studies (450)

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (1.56)	18.7374
1990's	8 (1.78)	18.2507
2000's	130 (28.89)	29.6817
2010's	291 (64.67)	24.3611
2020's	14 (3.11)	2.80

Authors

Authors	Studies
Ansari, K; Bhan, A; Chen, MY; Jandial, R	1
Ahmed, AU; Balyasnikova, IV; Burga, R; Castro, B; Cordero, A; Fares, J; Kanojia, D; Lee-Chang, C; Lesniak, MS; Miska, J; Petrosyan, E; Ramsey, MD; Rashidi, A; Schwartz, CW; Xiao, T; Zhang, P	1
Aydiner, A; Dogan, I; Ibis, K; Kizildag, I; Özkurt, S; Saip, P; Vatansever, S	1
Deng, Y; Li, X	1
Cui, Y; Dai, M; Hu, Y; Kong, W; Wang, X; Wu, H; Wu, J; Yu, B; Yu, X; Zhang, H; Zheng, Y	1
Arnaldez, FI; Derdak, J; Derse-Anthony, C; Dombi, E; Glod, J; Helman, L; Killian, JK; Linehan, WM; Meltzer, P; Miettinen, M; Spencer, M; Srinivasan, R; Steinberg, SM; Widemann, BC; Wiener, L	1
Ban, S; Chen, X; Li, X; Qian, J; Yang, J	1
Chen, AP; Cohen, JW; Derdak, J; Dombi, E; Dompierre, J; Glod, J; Goodwin, A; Kummar, S; O'Sullivan Coyne, G; Onukwubiri, U; Steinberg, SM; Widemann, BC	1
Bernards, N; Creemers, GJ; de Hingh, IHJT; Legué, LM; Lemmens, VEPP; van Erning, FN	1
Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q	1
Huang, JJ; Jiang, WQ; Kipps, TJ; Lin, X; Wu, L; Zhang, J; Zhang, S	1
Li, Q; Xie, D; Zhang, PF	1
Ding, HW; Fan, YH; Hong, JY; Kim, D; Lee, SK; Liu, JY; Wang, D; Xu, YN; Yang, XS	1
Chan, MWY; Chang, TS; Chen, WM; Chiang, MK; Hsieh, YY; Lu, CK; Tung, SY; Wei, KL; Wu, CS	1
Hou, X; Hua, X; Huang, Y; Peng, Z; Xie, T	1
Batra, A; Cheung, WY; Hannouf, MB; Rigo, R	1
Exman, P; Tolaney, SM	1
Hou, H; Kang, J; Li, D; Li, J; Li, X; Tian, W; Zhai, L; Zhong, Y	1
Isaacs, C; O'Regan, R; O'Shaughnessy, JA	1
Chen, S; Lensing, MM; Lyu, C; Wagner, KU; Weigel, RJ; Ye, Y	1
Bradbury, P; Chia, SK; Eisenhauer, E; Ellard, SL; Gelmon, K; Goodwin, R; Hagerman, L; Kumar, V; Lohrisch, C; Mates, M; Mihalcioiu, C; Miller, WH; Sakashita, S; Taylor, S; Tsao, MS; Wang, T; Welch, S	1
Ali, SM; Aparicio, S; Carney, WP; Chapman, JW; Crescnzo, RJ; Ellis, CE; Gelmon, KA; Ho, D; Huang, J; Leitzel, K; Lipton, A; Nomikos, D; Parulekar, WR; Shepherd, L; Virk, S; Zhu, L	1
Badovinac-Crnjevic, T; Ferrero, JM; Hoersch, S; Kim, SB; Krop, IE; LoRusso, PM; Martin, AG; Smitt, M; Wildiers, H	1
Atallah, JP; Ibrahim, U; Saqib, A	1
Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S	1
Amadori, D; Bongiovanni, A; De Vita, A; Ghetti, M; Ibrahim, T; La Manna, F; Liverani, C; Mercatali, L; Miserocchi, G; Recine, F; Spadazzi, C	1
Hadoux, J; Schlumberger, M	1
Burtness, B; Clement, PM; Cohen, EEW; Cong, XJ; Del Campo, JM; Dupuis, N; Ehrnrooth, E; Fayette, J; Gauler, T; Geoffrois, L; Gibson, N; Grau, JJ; Guigay, J; Haddad, RI; Krämer, N; Licitra, LF; Machiels, JH; Mailliez, A; Merlano, MC; Solca, F; Tahara, M; Vermorken, JB	1
Katsuta, E; Rashid, OM; Takabe, K	1
Boumber, Y; Chaudhary, S; Kesari, K; Khan, H; Khan, M; Smith, S; Wahab, A	1
Bagheri, N; Kosari, S; Madden, R; Peterson, GM; Thomas, J	1
Chang, DY; Chao, TY; Chen, TW; Cheng, AL; Chow, LW; Consortium, TBC; Hsieh, YY; Huang, SM; Lin, CH; Lu, YS; Yeh, DC	1
Baple, EL; Brooke, A; Derse-Anthony, C; Glod, J; Newbold, K; Osborne, N; Sturley, R; Thomas, N; Vaidya, B	1
Ding, C; Jiao, XD; Yu, G; Zang, YS	1
Chan, RT	1
Arumí, M; Bellet, M; Escrivá-de-Romaní, S; Saura, C	1
Abisoye-Ogunniyan, A; Davis, M; Ghebremedhin, A; Grizzle, W; Jones-Trich, J; Karanam, B; Lin, H; Salam, AB; Theodore, S; Wang, H; Yates, C	1
Andreou, M; Bermudez-Brito, M; de Bree, E; Goulielmaki, E; Makrigiannakis, A; Papakonstanti, EA; Tsentelierou, E; Tzardi, M; Tzenaki, N	1
Chemmalakuzhy, R; Lang, L; Shay, C; Teng, Y; Thakkar, P; Wang, X; Xiong, Y	1
Ahn, JH; Ahn, JS; Han, HS; Im, SA; Im, YH; Jung, KH; Kang, J; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Sohn, JH	1
Chung, JG; Hsu, FT; Lin, SS; Wu, JY	1
Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y	1
Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Wu, J; Yang, Y; Yi, C	1
Im, SA; Jung, HH; Jung, KH; Kim, JH; Kim, JY; Lee, E; Lee, KH; Lee, KS; Park, K; Park, WY; Park, YH; Sohn, J	1
Chen, J; Wang, J	1
Al-Janadi, A; Bolton, S; Flaig, T; Heath, E; Heilbrun, L; Hussain, A; Ivy, SP; Lara, P; Liu, G; Mack, P; Mannuel, H; Monk, JP; Silbiger, D; Smith, D; Stella, P; Usman, M; Vaishampayan, U; Zurita, A	1
Rongrong, S; Sun, S; Xiaowu, L; Yangmei, Z; Youwei, Z; Yuan, Y	1
Binglan, Z; Jing, Z; Rui, Z	1
Adelberg, D; Chau, CH; Choyke, PL; Dahut, WL; Figg, WD; Gulley, JL; Karakunnel, JJ; Madan, RA; Mulquin, M; Parnes, HL; Spencer, SD; Steinberg, SM; Turkbey, IB; Wright, J	1
Bingman, A; Carothers, S; Kraut, EH; Layman, RM; Lustberg, MB; Lynn, M; Mrozek, E; Ottman, S; Ramaswamy, B; Reinbolt, R; Ruppert, AS; Shapiro, CL; Wesolowski, R	1
Brooks, L; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Robertson, JD; Schmoll, HJ; Taboada, M; Wilson, D	1
Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K	1
Antoniani, B; Botti, C; Ciccarese, M; Cognetti, F; Di Benedetto, A; Ercolani, C; Fabi, A; Ferretti, G; Gori, S; Malaguti, P; Marino, M; Merola, R; Mottolese, M; Nisticò, C; Papaldo, P; Sperduti, I; Vici, P	1
Juhász, E; Kim, JH; Klingelschmitt, G; Walzer, S	1
Bayne, M; Cherrett, L; Davis, R; Fenton, P; Laurence, V	1
Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S	1
Brooks, L; Dearden, S; Hoff, PM; Jürgensmeier, JM; McWalter, G; Morgan, SR; Robertson, JD; Smith, JC; Wilson, D	1
Ahmed, S; Ammannagari, N; Bravin, EN; Patel, A	1
Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A	1
Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA	1
Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W	1
Du, J; Lu, YY; Su, SB; Wang, XF; Zhang, H; Zhang, TL; Zhou, QM	1
Adkins, D; Clark, J; Haddad, R; Jaffa, Z; Limaye, S; O'Neill, A; Posner, M; Riley, S; Zhao, S	1
Aikin, A; Balis, FM; Chuk, MK; Dombi, E; Fox, E; Lodish, M; Marcus, L; Merino, MJ; Steinberg, SM; Wells, SA; Whitcomb, PO; Widemann, BC	1
Gao, H; Guo, W; Liu, X	1
Costanzo, R; De Lutio, E; Franco, R; Montanino, A; Morabito, A; Normanno, N; Pasquale, R; Rachiglio, AM; Rocco, G; Sandomenico, C	1
Bartsch, R; Chrysikos, D; Dimopoulos, MA; Filipits, M; Papadimitriou, CA; Sergentanis, TN; Zagouri, F; Zografos, CG	1
Berglund, A; Bergström, D; De Pont Christensen, R; Fernebro, E; Frödin, JE; Garm Spindler, KL; Hagman, H; Jakobsen, A; Johnsson, A; Keldsen, N; Sundberg, J	1
Alencar, VM; Audeh, MW; Brown, K; Chan, A; de Oliveira, C; Hyams, DM; Klein, P; Lombard, J; Mookerjee, B; Snyder, R; Vinholes, J; Xu, J	1
Bennouna, J; Boyer, M; Geater, SL; Gorbunova, V; Hirsh, V; Kato, T; Lee, KH; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Schuler, M; Sequist, LV; Shah, R; Shahidi, M; Su, WC; Tsai, CM; Yamamoto, N; Yang, JC; Zazulina, V	1
Gradishar, WJ	1
Ramfidis, VS; Saif, MW; Syrigos, KN	1
Burris, HA; Crown, J; DeSilvio, M; Diéras, V; Espie, M; Kennedy, MJ; Koch, KM; Kothari, D; Lau, MR; Marty, M; Tresca, P	1
Higashiyama, S; Hosoi, H; Masui, T; Matsuura, N; Ota, I; Yane, K	1
Gustafson, DL; Hudachek, SF	1
Arribas, J; Baselga, J; Caratù, G; De Mattos-Arruda, L; Felip, E; Grueso, J; Hernández-Losa, J; Nuciforo, P; Parra, JL; Prudkin, L; Puente, XS; Scaltriti, M; Seoane, J; Serra, V; Silberschmidt, D; Vivancos, A	1
Basaran, G; Benekli, M; Cetin, B; Eralp, Y; Isikdogan, A; Karaca, H; Kucukoner, M; Onur, H; Ozkan, M; Saip, P; Sen, F; Un, O	1
Barker, HE; Chang, J; Cox, TR; Erler, JT; Martens, JW; Nicolau, MM; Wetterskog, D	1
Ahn, JS; Ahn, MJ; Cho, EK; Kang, ES; Kang, JH; Kim, SW; Lee, DH; Lee, GW; Lee, JS; Lee, JW; Lee, KH; Park, K; Sun, JM	1
Bahra, M; Ehemann, V; Endris, V; Goeppert, B; Kamphues, C; Klauschen, F; Lorenz, K; Muckenhuber, A; Neuhaus, P; Sinn, B; Stenzinger, A; Warth, A; Weichert, W	1
Amantini, C; Berardi, R; Burattini, L; Cascinu, S; Conti, A; Muzzonigro, G; Santoni, G; Santoni, M	1
Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC	1
Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J	1
Akinaga, S; Fujisaka, Y; Hayashi, H; Hirashima, T; Miyoshi, K; Murakami, H; Nakagawa, K; Satouchi, M; Takahashi, T; Takeda, K; Yamamoto, N	1
Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF	1
Bennouna, J; Dansin, E; Favrel, S; Hiret, S; Kowalski, D; Krzakowski, M; Penel, N; Tourani, JM	1
Fan, Y; Li, HH; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P	1
Alghamdi, W; Cooper, MR; Shaheen, DJ; Steinberg, M; Yi, SY	1
Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G	1
Fu, S; Jiang, L; Lin, YB; Long, H; Shao, JY; Su, XD; Wang, F; Wang, JF; Zhang, SL; Zhang, YG; Zhao, ZR	1
Brambilla, E; Busser, B; Cadranel, J; Coll, JL; Hurbin, A; Jeannot, V; Robin, B; Wislez, M	1
Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E	1
Bian, L; Du, G; Guo, YF; Jiang, ZF; Li, W; Song, ST; Wang, T; Wu, SK; Zhang, HQ; Zhang, SH	1
Amiri Kordestani, L; Blumenthal, G; Booth, B; Cortazar, P; Ibrahim, A; Justice, R; Liu, Q; Mehrotra, N; Rahman, A; Schrieber, S; Song, P; Tang, S; Wang, J; Wang, Y; Xu, Q	1
Bloomfield, D; de Bono, JS; Fong, PC; Heath, C; Hickish, T; Jenkins, P; Jones, RJ; Karavasilis, V; Lumsden, G; Molife, LR; O'Sullivan, JM; Olmos, D; Omlin, A; Oommen, N; Pedley, I; Pelling, K; Temple, G; Thompson, E; Wheatley, D	1
Agelaki, S; Georgoulias, V; Kallergi, G; Kalykaki, A; Mavroudis, D; Xyrafas, A	1
Basaran, G; Cabuk, D; Dane, F; Korkmaz, T; Seber, S; Telli, F; Teomete, M; Turhal, S; Yumuk, PF	1
Barinow-Wojewódzki, A; Krawczyk, P; Kucharczyk, T; Milanowski, J; Milecki, P; Powrózek, T; Ramlau, R; Sura, S; Szumiło, J; Szyszka-Barth, K; Walczyna, B; Wojas-Krawczyk, K	1
Guan, YS; He, Q; Li, M	1
Benekli, M; Bozkurt, O; Buyukberber, S; Ciltas, A; Demirci, U; Eren, T; Isikdogan, A; Kaplan, MA; Karaca, H; Kodaz, H; Ozkan, M; Sevinc, A	1
Behringer, D; Desaiah, D; Dittrich, C; Hartmann, JT; Kazeem, G; Leschinger, MI; Papai-Szekely, Z; Sederholm, C; Vinolas, N; von Pawel, J	1
Chang, CX; Li, P; Qi, JL; Shi, SB; Tang, XY; Tian, J	1
Ahn, JS; Ahn, MJ; Lee, JY; Lim, SH; Park, K; Sun, JM	1
Inoue, T; Iyoda, T; Uetsuka, Y; Yamamoto, W	1
Köhler, J; Schuler, M	1
Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A	1
Bexon, AS; Boyd, TE; Conkling, P; de La Bourdonnaye, G; Mita, AC; Nemunaitis, JJ; Richards, DA; Smith, DA; Wages, D	1
Ali, SM; Chan, CA; Halmos, B; Jia, Y; Miller, VA; Saad, S	1
Barni, S; Borgonovo, K; Coinu, A; Ghidini, A; Petrelli, F	1
Christopoulou, A; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katopodis, O; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Polyzos, A; Souglakos, J; Stathopoulos, E	1
de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A	1
Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M	1
DeSilvio, M; Ellis, C; Guan, Z; Jiang, Z; Leigh, M; Russo, M; Shen, Z; Tong, Z; Xu, B; Yang, J	1
Blanchet, B; Cessot, A; Goldwasser, F	1
Awada, A; Bogaerts, J; Brain, E; Cardoso, F; Fumoleau, P; Hayward, L; Koch, KM; Lokiec, F; Marréaud, S; Rezai, K; Werutsky, G	1
Auten, JJ; Cicci, TA; Corrigan, PA; Lowe, DK	1
Bevilacqua, S; D'Alessio, A; De Luca, A; Frezzetti, D; Gallo, M; Maiello, MR; Morabito, A; Normanno, N; Perrone, F	1
Bosch-Barrera, J; Brunet, J; Izquierdo, A; Lorencio, C; Menéndez, JA; Porta, R; Rosell, R; Sais, E; Sirvent, JM	1
Fuereder, T; Hoeflmayer, D; Kornek, G; Kuehrer, I; Scheithauer, W; Stift, J; Stranzl, N	1
He, J; Li, YS; Wei, X; Yu, FF; Zhang, TY; Zhang, X; Zhang, XJ	1
Ablack, A; Carmine-Simmen, K; Chambers, AF; Chien, AE; Chin, CA; Courtneidge, SA; Hague, MN; Leith, SJ; Leong, HS; Lewis, JD; McPherson, VA; Postenka, CO; Robertson, AE; Stoletov, K; Turley, EA	1
Banna, G; Cappuzzo, F; Catino, A; Chiari, R; Cortinovis, D; Crinò, L; D'Incecco, A; de Marinis, F; Facchinetti, F; Galetta, D; GiajLevra, M; Haspinger, ER; Landi, L; Milella, M; Minuti, G; Novello, S; Ricciardi, S; Rossi, E; Salvini, J; Santo, A; Tibaldi, C; Tiseo, M	1
Aprile, G; Ciuleanu, T; Csutor, Z; Federowicz, I; Fittipaldo, A; Hsu, C; Klughammer, B; Li, CP; Lipp, R; Meng, X; Moore, M; Nowara, E; Stemmer, SM; Tham, CK; Van Cutsem, E; Van Laethem, JL; Zeaiter, A	1
Boukovinas, I; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalogera-Fountzila, A; Karavasilis, V; Klouvas, G; Kosmidis, P; Kotoula, V; Mavropoulou, P; Papandreou, CN; Pectasides, D; Syrigos, KN	1
Fukuoka, M; Imamura, F; Komuta, K; Kudoh, S; Seki, A; Yoshioka, H	1
Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B	1
Shawky, H; Tawfik, H	1
Ferrer, L; Ferretti, G; Meynet, E; Moro-Sibilot, D; Pirvu, A; Sakhri, L	1
Engle, JA; Kolesar, JM	1
Baron-Hay, S; Bauwens, A; Chan, A; Craft, P; de Boer, R; Kotasek, D; Redfern, A; Shannon, C; Townsend, A; Webb, S	1
Bastida, CC; Falchook, GS; Gaido, L; Jackson, T; Karp, DD; Miller, VA; Ordóñez, NG; Stephens, PJ	1
Hatcher, H; Laing, R; Pelling, K; Plummer, R; Ring, A; Schnell, D; Temple, G; Uttenreuther-Fischer, M; Wheatley, D	1
Chen, LK; Dinglin, XX; Hou, X; Huang, JJ; Ma, SX; Qin, T; Wang, Z; Zeng, YD	1
Coussy, F; Cuvier, C; Espié, M; Giacchetti, S; Hocini, H; Teixeira, L	1
Chen, H; Du, N; Li, F; Yang, P; Zhao, X; Zhu, G	1
Cheng, Y; Fan, Y; Han, B; Huang, C; Liu, X; Liu, Y; Lu, S; Ma, S; Song, X; Wang, J; Wang, M; Yang, S; Zhang, L; Zhang, S; Zhao, H; Zhou, C	1
George, VC; Kumar, DR; Kumar, RA; Suresh, PK	1
Balanis, NG; Carlin, CR; Pascuzzi, PE; Schiemann, BJ; Schiemann, WP; Wendt, MK; Williams, WK	1
Azzariti, A; Cocco, T; Ferretta, A; Guida, G; Guida, M; Guida, S; Iacobazzi, RM; Maida, I; Porcelli, L; Quatrale, AE; Sidella, L; Stolfa, DA; Strippoli, S; Tommasi, S	1
Kaur, J; Tikoo, K	1
Kaneko, T; Lau, MR; Lunec, J; Margetts, J; Novello, S; Nutt, J; Plummer, R; Ramlau, R; Reck, M; Scagliotti, GV; Thomas, M	1
Biganzoli, L; Dambrosio, M; Minelli, M; Molteni, L; Montemurro, F; Mustacchi, G; Pronzato, P; Scaltriti, L	1
Chen, LK; Dinglin, XX; Liang, JZ; Liao, H; Ma, SX; Qin, T; Wei, WD; Xu, F; Zeng, YD; Zhang, L	1
Kempf, E; Le Chevalier, T; Planchard, D; Soria, JC	1
Caponigro, F; Clement, PM; Cohen, EE; Cong, XJ; Cupissol, D; de Castro, G; de Souza Viana, L; Del Campo, JM; Ehrnrooth, E; Fayette, J; Gauler, T; Grau, JJ; Guigay, J; Haddad, RI; Keilholz, U; Licitra, LF; Machiels, JP; Tahara, M; Vermorken, JB	2
Aogi, K; Armour, A; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Nakayama, T; Nishimura, Y; Rai, Y; Sasaki, Y; Shimizu, S	1
Karedan, T; Perez, CA; Wang, E	1
Arpaci, E; Arslan, UY; Artac, M; Bayoglu, IV; Demirci, U; Dogan, M; Guler, T; Isikdogan, A; Koca, D; Kucukoner, M; Kucukzeybek, Y; Oguz, A; Turker, I; Uncu, D; Zengin, N	1
Bourhis, J; Economopoulou, P; Psyrri, A	1
Anto, RJ; Antony, J; Chandran, H; Joseph, SM; Katiki, MR; Murty, MS; Nath, LR; Nishanth, KS; Panakkal, EJ; Paul, A; Rajan, E; Ran, S; Saikia, M; Sankar, S; Shabna, A; Sridivya, I; Sriramya, I; Vinod, V	1
Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I	1
Al-Foheidi, M; Al-Rehaily, S; Darwish, T; Karim, SM; Mahrous, M; Mansour, M; Mokhtar, M; Rizvi, A; Zekri, J	1
Moser, A; Piwko, C; Pollex, E; Prady, C; Yunger, S	1
Fan, Y; Fang, L; Gong, L; Huang, Z; Lei, T; Mao, W; Miao, L; Yang, H; Yu, H	1
Arteaga, CL; Barry, WT; Dees, EC; Falkson, CI; Guo, H; Hobday, TJ; Krop, IE; Lin, NU; Mayer, IA; Najita, JS; Nanda, R; Richardson, AL; Rimawi, MF; Ryabin, N; Van den Abbeele, AD; Winer, EP; Wolff, AC; Yap, JT	1
Sala González, MÁ	1
Casanova, C; Dazzi, C; Mazza, V; Verlicchi, A	1
Adamo, V; Ferraro, G; Franchina, T; Giordano, A; Picone, A; Ricciardi, GR; Russo, A; Toscano, G; Zanghì, M	1
De Smet, M; Herremans, C; Liu, D; Machiels, JP; Peeters, M; Pilz, K; Rottey, S; Specenier, P; Strelkowa, N; Surmont, V	1
Alunni-Fabbroni, M; de Gregorio, N; Fehm, T; Friedl, TW; Hartkopf, A; Huober, J; Janni, W; Meier-Stiegen, F; Müller, V; Pantel, K; Rack, B; Schneeweiss, A; Schochter, F; Scholz, C; Schramm, A; Taran, FA; Trapp, E; Wallwiener, D	1
Bitterman, H; Feldhamer, I; Greenberg-Dotan, S; Hammerman, A; Yerushalmi, R	1
Ahmed, RS; Gururajan, M; Karrison, T; O'Donnell, PH; Posadas, EM; Shen, J; Sievert, M; Stadler, WM; Szmulewitz, RZ; Wade, JL	1
Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M	1
Buck, AK; Grelle, I; Hänscheid, H; Herrmann, K; Higuchi, T; Lapa, C; Lückerath, K; Muegge, DO; Reiners, C; Schmid, JS; Werner, RA	1
Bièche, I; Bonin, F; Château-Joubert, S; de Plater, L; Dieras, V; El Botty, R; Hatem, R; Labiod, D; Marangoni, E; Servely, JL; Vacher, S	1
Bian, L; Du, G; Guo, Y; Jiang, Z; Song, S; Wang, T; Xu, X; Zhang, S; Zhuo, J	1
Chen, X; Ding, L; Jin, L; Liang, GK; Wu, HH; Yao, ZT; Zhang, JQ	1
Ackerman, C; Beltran, L; Bhal, A; Boleti, E; Brown, J; Chowdhury, S; Crabb, S; Dunlop, J; Fife, K; Geldart, T; Hall, PE; Hawkins, R; Hill, R; Jones, R; Larkin, J; McLaren, D; Nathan, P; Powles, T; Ralph, C; Webb, A	1
Boye, M; Kang, JH; Kim, JS; Orlando, M; Puri, T; Rajan, N; Srimuninnimit, V; Tsai, CM; Wang, X; Yang, JC	1
Chen, SC; Goeldner, RG; Harbeck, N; Huang, CS; Hurvitz, S; Im, SA; Im, YH; Jassem, J; Jung, KH; Piccart-Gebhart, M; Ro, J; Shao, Z; Shen, K; Sun, Q; Uttenreuther-Fischer, M; Wojtukiewicz, M; Xu, B; Yeh, DC; Zhang, Q	1
Hirsh, V; Massey, D; Mok, T; O'Byrne, K; Popat, S; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V	1
Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L	1
Griggs, JJ; Hayes, DF; Henry, NL; Kidwell, KM; Merajver, SD; Murthy, P; Schott, AF; Smerage, JD; Van Poznak, CH; Wicha, MS	1
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S	1
Harvey, R; Simpson, E; Squires, H; Stevens, J; Stevenson, M	1
Choy, TS; Kwong, DL; Lam, KO; Lam, PM; Lee, VH; Leung, DK; Leung, TW	1
Bernards, R; Brunen, D; de Bree, R; Koole, K; Lieftink, C; Noorlag, R; van Es, RJ; van Kempen, PM; Willems, SM	1
Blumenthal, GM; He, K; Kazandjian, D; Keegan, P; Pazdur, R; Yuan, W	1
Huo, LM; Sun, HT; Tian, JH; Xu, JG; Yang, G; Yang, KH; Zhang, P; Zheng, MH	1
Amatu, A; Bardelli, A; Bencardino, K; Bergamo, F; Bertotti, A; Cassingena, A; Ciardiello, F; Comoglio, PM; Depetris, I; Ghezzi, S; Lauricella, C; Leone, F; Lonardi, S; Marrapese, G; Marsoni, S; Martinelli, E; Martino, C; Palmeri, L; Racca, P; Regge, D; Sartore-Bianchi, A; Siena, S; Siravegna, G; Torri, V; Troiani, T; Trusolino, L; Valtorta, E; Vanzulli, A; Veronese, S; Zagonel, V	1
Bagley, S; Bauml, J; Cohen, RB; Hayes, DN; Hwang, WT; Langer, C; Olson, JG; Weiss, JM	1
Barni, S; Bisagni, G; Bogina, G; Duranti, S; Fabi, A; Fiorio, E; Foglietta, J; Gori, S; Inno, A; Leonardi, V; Lunardi, G; Marchetti, F; Montemurro, F; Pavese, I; Pellegrino, A; Rossi, V; Santini, D; Saracchini, S; Turazza, M; Vici, P; Zambelli, A	1
Huang, XX; Mao, SS; Wu, JS; Xiong, J; Yu, XN	1
Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M	1
Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA	1
Ahn, MJ; Bai, Y; Chen, K; Cheng, Z; Guo, Q; Kim, DW; Rabbie, S; Wang, Y; Xu, Y; Yang, JC; Yang, Z; Yin, X; Zhang, L; Zhang, X	1
Fulton, AM; Kochel, TJ; Kundu, N; Ma, X; Reader, JC	1
Ali, SM; Allen, JM; Erlich, RL; Miller, VA; Ou, SI; Ross, JS; Schrock, AB; Stephens, PJ; Vafai, D	1
Go, YJ; Han, JY; Joo, J; Lee, GK; Lee, JS; Lee, KH; Lee, SH; Lee, Y; Lim, KY	1
Buskens, E; de Bock, GH; Greuter, MJW; Koleva-Kolarova, RG; Oktora, MP; Reyners, AKL; Robijn, AL	1
Chen, H; Gao, S; Guo, JH; Li, XT; Wang, XD; Zhang, HY; Zhang, PJ; Zhu, X	1
Benowitz, S	1
Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M	1
Paul, B; Thompson, J; Trovato, JA	1
Spector, N	1
Halterman, PA	1
Arteaga, CL; Davidson, NE; Moulder, SL; O'Neill, A; Pins, M; Sledge, GW; Sparano, JA	1
Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R	1
Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P	1
Arbushites, MC; Aziz, Z; Bines, J; Dering, J; Di Leo, A; Finn, RS; Gomez, HL; Guerrera, SF; Koehler, M; Oliva, C; Press, MF; Stein, SH; Williams, LS; Zvirbule, Z	1
Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI	1
Dobrova, NV; Lichinitser, MR; Semenov, NN; Vakhabova, JV	1
Bareschino, M; Colantuoni, G; Falanga, M; Ferrara, ML; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A; Rossi, E; Schettino, C	1
Hay, JW; Le, QA	1
Ailawadhi, S; Derby, L; Fetterly, G; Natarajan, R; Ramnath, N; Reid, M	1
Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC	1
JuanYin, J; Kelly, K; Koretsky, A; Munasinghe, J; Shapiro, E; Tracy, K; Zhang, L	1
Bennouna, J; Cosaert, J; Gill, S; Humblet, Y; Moore, MJ; Scheithauer, W; Shang, A; Van Cutsem, E; Van Laethem, JL; Verslype, C; Vervenne, WL	1
Boyer, MJ; Davis, ID; Gurney, H; Kotasek, D; Pezaro, C; Rosenthal, MA; Solomon, B; Toner, GC; Underhill, C	1
Kunitoh, H; Saijo, N; Takeuchi, M	1
Arteaga, CL; Boimel, PJ; Coniglio, SJ; Hynes, NE; Kedrin, D; Segall, JE; Wyckoff, J	1
Jiang, W; Wu, JX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY	1
Da Silva, S; Decaestecker, C; Demetter, P; Mathieu, A; Salmon, I; Verbeken, E; Weynand, B	1
Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD	1
Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C	1
Sanford, M; Scott, LJ	1
Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A	1
Atkins, JN; Crawford, ED; Goodwin, JW; Kakhil, SR; Lange, MK; Mansukhani, M; Petrylak, DP; Tangen, CM; Twardowski, PW; Van Veldhuizen, PJ	1
Wicha, MS	1
Dean, E; Hamilton, M; Judson, I; McCarthy, S; Ranson, M; Reid, A; Shaw, H; Wolf, J	1
Ardinghi, C; Bani, MR; Bernasconi, S; Carraro, F; Ghilardi, C; Giavazzi, R; Naldini, A; Oliva, P; Silini, A	1
Ma, PC; Manson, GV	1
Amonkar, MM; Aziz, Z; Bines, J; Di Leo, A; Gomez, HL; Sherrill, B; Wu, Y; Zvirbule, Z	1
Amir, E; Clemons, M; Freedman, O; Ocaña, A; Seruga, B	1
Baselga, J; Bischoff, J; Blackwell, KL; Burstein, HJ; Casey, M; Ellis, C; Koehler, M; O'Shaughnessy, J; Rugo, H; Sledge, G; Storniolo, AM; Vukelja, S	1
Brandes, AA; Degli Esposti, R; Franceschi, E; Tosoni, A	1
Arbushites, M; Di Leo, A; Downey, L; Guzman, R; Koehler, M; Livingston, RB; Press, MF; Santiago, A; Villalobos, I; Williams, L	1
Ferraz, MB; Puga, ME; Riera, R; Soárez, PC	1
Liao, XB; Liu, JQ; Sun, XL; Wang, YX; Yan, DF; Yan, SX; Yang, JS	1
Chen, J; Gully, CP; Lee, MH; Velazquez-Torres, G; Wang, E; Yeung, JA; Yeung, SC; Zhang, F	1
Han, YH; Kim, SW; Lee, DH; Lee, JS; Suh, C	1
Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C	1
Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ	1
Hasegawa, S; Hashimoto, M; Kondo, N; Matsumoto, S; Okumura, Y; Takuwa, T; Tanaka, F; Torii, I; Yoneda, K	1
Haddad, R; Krebs, A; Paz-Ares, L; Robinson, BG; Vasselli, J	1
Camps, C; Carcereny, E; Gasco, A; Massuti, B; Moran, T; Quiroga, V; Rosell, R; Viteri, S; Wei, J	1
Huang, W; Jia, H; Ma, J; Tan, L; Wu, J; Yan, H; Yang, S; Zeng, M; Zhu, X; Zuo, Y	1
Besse, B; Buisine, MP; Copin, MC; Dansin, E; Ferté, C; Parent, F; Penel, N; Soria, JC	1
Pownall, M	1
Catot, S; Colomer, R; de Castro, J; Guillem, V; Gúrpide, A; Isla, D; Lianes, P; Massutí, B; Mayo, C; Paz-Ares, L; Polo, E; Porta, R; Pradas, A; Puig, T; Queralt, C; Reguart, N; Rosell, R; Salinas, P; Sánchez-Torres, JM; Tarón, M	1
Curran, MP	1
Kaley, K; Penney, R; Saif, MW; Syrigos, K	1
Backes, WH; Brans, B; de Langen, AJ; Dingemans, AC; Groen, HJM; Hoekstra, OS; Marcus, JT; Pruim, J; Scholtens, HTGM; Smit, EF; Thunnissen, FB; van den Boogaart, V; van Tinteren, H	1
Chopra, A; Ku, GY; Lopes, Gde L	1
Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I	1
Fukuhara, A; Hatachi, Y; Kim, YH; Kubo, T; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Togashi, K; Togashi, Y	1
Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V	1
Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N	1
Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL	1
de Weger, RA; Moelans, CB; van Diest, PJ	1
Kickler, TS; Lynch, DR; Rade, JJ	1
Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N	1
Fridlyand, J; Fyfe, G; Kaiser, LD	1
Morioka, T; Niikura, N; Okamura, T; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B	1
Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B	1
Chen, X; Guo, R; Shu, Y; Sun, J; Wang, T; Zhang, Z	1
Cataldo, VD; Gibbons, DL; Pérez-Soler, R; Quintás-Cardama, A	1
Alcindor, T; Au, HJ; Jarvi, A; MacAlpine, K; Mackay, HJ; McWhirter, E; Oza, AM; Wang, L; Wright, JJ	1
Hirano, S; Ishii, S; Kobayashi, N; Kudo, K; Naka, G; Sugiyama, H; Takeda, Y	1
Cabebe, EC; Fisher, GA; Sikic, BI	1
Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY	1
Amonkar, MM; Baselga, J; Blackwell, KL; Burstein, HJ; Ellis, C; O'Shaughnessy, J; Sherrill, BH; Wu, Y	1
Ali, SM; Carney, W; Gagnon, R; Leitzel, K; Lipton, A; Maltzman, J; Martin, AM; Platek, G; Steplewski, K; Westlund, R	1
Adenis, A; Conroy, T; Gavoille, C	1
Abdiche, S; Bonnabau, H; Chouaïd, C; Cumin, I; Decroisette, Ch; Ejnaini, CN; Hureaux, J; Lombard, JN; Mazières, J; Monnet, I; Quéré, G; Vergnenègre, A	1
Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K	1
Chen, KT; Chiu, YJ; Chuang, YH; Chung, JG; Hour, MJ; Kuo, SC; Lu, CC; Tsai, SC; Yang, JS	1
Abbruzzi, A; Bromberg, J; Caravelli, J; Dang, C; Gucalp, A; Hudis, C; Massague, J; Norton, L; Patil, S; Pellegrino, C; Santamauro, J; Sparano, JA; Theodoulou, M; Traina, TA	1
Akerley, WL; Arthur, S; Brugger, W; Chen, Y; Costa, DB; Ferrari, D; Garmey, EG; Gerber, DE; Gorbachevsky, I; Orlov, S; Ramlau, R; Schiller, JH; Schwartz, B; Sequist, LV; von Pawel, J	1
Commander, H; Perry, C; Whiteside, G	1
Dao, KM; DiCarlo, B; Elashoff, R; Hecht, JR; Lin, LS; Park, DJ; Patel, R; Ryba, N; Wainberg, ZA; Wang, HJ	1
Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P	1
Jou, YS; Ko, JY; Lin, KT; Lin, SC; Tu, PH; Wang, YW	1
Adelstein, DJ; Ives, DI; Rice, TW; Rodriguez, CP; Rybicki, LA	1
Bignon, YJ; Cayre, A; El Guerrab, A; Nemlin, CC; Penault-Llorca, F; Rossignol, F; Vigier, F; Zegrour, R	1
Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W	1
Baudin, E; Dralle, H; Elisei, R; Fagin, JA; Gagel, RF; Jarzab, B; Langmuir, P; Read, J; Robinson, BG; Ryan, AJ; Santoro, M; Schlumberger, MJ; Vasselli, JR; Wells, SA	1
Bisagni, G; Clavarezza, M; Cognetti, F; Crivellari, D; Fabi, A; Ferzi, A; Foglietta, J; Gamucci, T; Gori, S; Metro, G; Montemurro, F; Silva, RR; Spazzapan, S; Stocchi, L; Torrisi, E	1
Chung, C; Frankel, P; Gu, L; Hurria, A; Kane, SE; Koczywas, M; Lau, SK; Leong, L; Luu, T; Martel, CL; McNamara, M; Morgan, R; Ruel, C; Russell, CA; Somlo, G	1
Barberis, M; Catania, C; De Pas, TM; Giovannini, M; Labianca, R; Manzotti, M; Spaggiari, L; Toffalorio, F; Trifirò, G	1
Asmis, TR; Hilton, JF; Jonker, DJ; Moore, MJ; O'Callaghan, CJ; Parulekar, W; Powell, ED; Tu, D; Vickers, MM	1
Benoit, A; Cho, TH; de la Fouchardière, C; Derbel, O; Duplomb, S; Mechtouff-Cimarelli, L; Peix, JL	1
Gabr, AG; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Moriya, Y; Nishioka, Y; Ogawa, H; Saijo, A; Sakaguchi, S; Sone, S; Suzuki, M; Trung, VT	1
Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM	1
Arbushites, MC; Chien, AJ; Dickler, MN; Franco, SX; Glencer, A; Hudis, C; Lahiri, S; Nulsen, B; Park, JW; Rugo, HS; Scott, J; Stopeck, AT	1
Agulnik, M	1
Carli, P; Crivellari, D; Di Lauro, V; Dolcetti, R; Lamaj, E; Miolo, G; Quitadamo, D; Spada, A; Spazzapan, S; Turchet, E; Veronesi, A	1
Bazzan, AJ; Deshmukh, S; Levine, M; Littman, S; Mitchell, E; Monti, DA; Newberg, AB; Pillai, MV; Yeo, CJ; Zabrecky, G	1
Böker, B; Grohé, C; Lüders, H	1
Liu, BX; Ying, JE; Zhu, LM	1
Fan, Q; Li, P; Ma, Z; Qi, G; Wang, H; Wang, Q; Yan, X; Zhang, G; Zhu, H	1
Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T	1
Carey, LA; Cleator, S; Frakes, L; Garcia, AA; Hickish, T; Houston, S; Jones, H; Kelly, S; Lin, NU; Mendelson, D; Munster, P; Uttenreuther-Fischer, M; Vinisko, R; Wheatley, D; Wind, S; Winer, EP	1
Bekaii-Saab, T; O'Neil, B; Peck, J; Villalona Calero, M; Wei, L; Zalupski, M	1
Beijnen, JH; Guchelaar, HJ; Opdam, FL; Schellens, JH	1
Bagnato, A; Cianfrocca, R; Di Castro, V; Rosanò, L; Spinella, F; Tocci, P	1
Feng, ZH; Li, D; Liao, SJ; Shu, Y; Sun, R; Wang, Q; Wei, JJ; Yan, B; Yuan, Y; Zhang, GM; Zhou, YH; Zhu, JH	1
Agulnik, M; Blair, EA; Cohen, EE; Dekker, A; Grushko, TA; Olopade, OI; Perez, CA; Raez, LE; Seiwert, TY; Song, H; Stenson, K; Vokes, EE	1
Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G	1
Arango, N; Bonilla, C; Cuello, J; Llinás, N; Rivas, G; Rubiano, J	1
Amler, L; Girish, S; Guardino, E; Krop, IE; LoRusso, P; Lu, M; Miller, KD; Modi, S; Rodriguez, G; Rugo, HS; Winer, EP; Yardley, D; Zheng, M	1
Chang, LS; Chiu, CC; Hsieh, CY; Lin, SR; Tsai, PC; Wang, CK	1
Arbushites, MC; Bernini, P; Bertini, I; Biganzoli, L; Cappadona, S; Claudino, WM; Di Leo, A; Luchinat, C; Nepi, S; Oakman, C; Tenori, L	1
Abrams, TA; Ancukiewicz, M; Blaszkowsky, L; Chan, JA; Duda, DG; Elliott, M; Enzinger, PC; Goldstein, M; Jain, RK; Kulke, MH; Meyerhardt, JA; Regan, E; Schrag, D; Wolpin, BM; Zhu, AX	1
Frampton, JE	1
Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R	1
Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T	1
Awada, A; Beckmann, MW; Besse-Hammer, T; Canon, JL; De Grève, J; Dirix, L; Fasching, PA; Fleischer, F; Gottschalk, N; Harbeck, N; Harter, P; Jonat, W; Neven, P; Piccart, M; Possinger, K; Schmidt, M; Schuler, M; Schütte, J; Uttenreuther-Fischer, M; Wind, S	1
Braunfeld, J; Brekken, RA; Burrows, FJ; Carbon, JG; Kirane, A; Ostapoff, K; Schwarz, RE; Toombs, JE; Zaknoen, S	1
Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J	1
Amagaya, S; Chang, CM; Chang, PY; Chen, MY; Jao, HY; Kuo, SC; Lee, CY; Lu, CC; Tu, MG; Yang, JS	1
Frampton, JE; Keating, GM; Lyseng-Williamson, KA	1
Deng, X; Erfani, SF; Hemler, ME; Hoff, J; Jin, H; Kaetzel, DM; Li, Q; Novak, M; Rabinovitz, I; Sharma, C; Sonnenberg, A; Stipp, CS; Yang, H; Yang, XH; Yi, Y; Zhou, P	1
Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B	1
Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G	1
Assaf, E; Bouaita, L; Culine, S; Delbaldo, C; Pouessel, D; Sellam, Z; Verlinde-Carvalho, M	1
Baselga, J; Blackwell, K; Diéras, V; Fang, L; Gianni, L; Guardino, E; Krop, IE; Lu, MW; Miles, D; Oh, DY; Olsen, S; Pegram, M; Verma, S; Welslau, M	1
Clark, JI; Gajewski, TF; Gangadhar, TC; Karrison, T	1
Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A	1
Acierno, R; Alberti, S; del Boccio, P; Giannelli, G; Maffia, M; Pieragostino, D; Sacchetta, P; Salzet, M; Simeone, P; Tinelli, A; Toto, C; Vergara, D	1
Haglund, C; Hermunen, K; Osterlund, P	1
Cai, Y; Chen, G; Jia, J; Liu, B; Liu, H; Liu, JY; Zhang, JL; Zhang, W; Zhao, YF; Zhong, HY	1
Akerley, W; Boucher, K; Bylund, J; Egbert, L; Harker, G; Reddy, C; Rich, N; Van Duren, T	1
Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, Y; Wang, ZP; Zhang, XR	1
Cunningham, D; D'Haens, G; Douillard, JY; Robertson, J; Stone, AM; Van Cutsem, E; Wong, RP	1
Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Kim, YT; Kim, YW; Lee, SH; Park, JH	1
Alba, E; Álvarez, M; de Luque, V; González-Hermoso, C; Jerez, JM; Medina, JA; Pajares, B; Rueda, A; Toledo, MD; Trigo, JM	1
Arcaroli, J; Dasari, A; Erlichman, C; Foster, NR; Hidalgo, M; McManus, M; Messersmith, WA; Nallapareddy, S; Picus, J; Powell, R; Quackenbush, K; Tan, AC; Wright, J	1
Chen, EX; Haider, MA; Halford, R; Hotte, SJ; Ivy, SP; Kollmannsberger, C; Mackenzie, MJ; Moore, MJ; Mukherjee, SD; Murray, N; Sridhar, SS; Tannock, IF; Wang, L	1
Balteskard, L; Edna, TH; Laino, R; Norum, J; Rønning, G; Wählby, L	1
Fishman, AD; Wadler, S	1
Arteaga, CL; Ritter, CA	1
Cohen, EE; Huo, D; Recant, W; Rosen, F; Stadler, WM; Stenson, K; Vokes, EE	1
Matsuo, M; Saiki, I; Sakurai, H	1
Boige, V; Ducreux, M	1
Batist, G; Daneshmand, M; Goss, G; Hirte, HW; Lorimer, IA; Major, P; Matthews, S; Miller, WH; Parolin, DA; Seymour, L; Stewart, D	1
Bartolini, S; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, G; Crino, L; de Rosa, M; Gregorc, V; Lombardo, L; Magrini, E; Paties, CT; Rossi, E; Villa, E	1
Arteaga, CL; Moulder, SL	1
Bonsignori, M; Delprete, S; La Cesa, A; Marcucci, F; Massacesi, C; Rocchi, MB; Santini, D; Tonini, G; Vincenzi, B	1
Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L	1
Yamada, K; Yamaguchi, S; Yamamura, T	1
Averbuch, SD	1
Schiller, JH	1
Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H	1
Agarwala, SS; Hidalgo, M; Senzer, NN; Siu, LL; Soulieres, D; Vokes, EE	1
Cats, A	1
Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G	1
Bianco, V; Bonsignori, M; Campisi, C; D'Angelillo, RM; Marcucci, F; Massacesi, C; Pilone, A; Santini, D; Tonini, G; Vincenzi, B	1
Bacharach, SL; Berman, A; Brahim, JS; Carrasquillo, JA; Chow, C; Ettenberg, SA; Figg, WD; Hewitt, SM; Lepper, ER; Lipkowitz, S; Parr, AL; Sparreboom, A; Steinberg, SM; Swain, SM; Tan, AR; Whatley, M; Yang, X	1
de Waal, R; Heerschap, A; Küsters, B; Leenders, WP; Maass, C; Ruiter, D; Ryan, A; Verrijp, K; Wesseling, P	1
Chambers, AF; Ellis, CG; Groom, AC; MacDonald, IC; Mackenzie, LT; Ryan, A; Varghese, HJ	1
Aggarwal, BB; Kobayashi, Y; Takada, Y	1
Araki, J; Ichikawa, Y; Okamoto, I; Sasaki, J; Suto, R	1
Choo, MK; Koizumi, K; Matsuo, M; Saiki, I; Sakurai, H; Ueno, Y	1
Barge, A; Baselga, J; Miller, KD; Rowbottom, J; Sledge, G; Trigo, JM; Wheeler, C	1
Alleva, AM; Cole, GW; Maxhimer, JB; Nguyen, DM; Reddy, RM; Schrump, DS; Zuo, J	1
Angelucci, A; Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C	1
Drevs, J; Esser, N; Konerding, MA; Ogilvie, DJ; Ryan, AJ; Wedge, SR; Wolloscheck, T	1
Astoul, P; Barlési, F; Doddoli, C; Greillier, L; Kleisbauer, JP; Tchouhadjian, C; Thomas, P; Villani, P	1
Blackwell, KL; Burris, HA; Dees, EC; Dowlati, A; Ellis, MJ; Harris, JL; Hurwitz, HI; Jones, SF; Koch, KM; Mangum, S; Marcom, PK; O'Neil, B; Overmoyer, B; Smith, DA; Spector, NL; Stead, A	1
Bauer, JA; Cerny, T; Egli, F; Gillessen, S; Jermann, M; Joerger, M; Morant, R; Pless, M; Rhyner, K; Salzberg, M; Stahel, RA	1
Arao, T; Koizumi, F; Nishio, K; Shiratori, Y; Takeda, M; Takigahira, M; Yanagihara, K	1
Edakuni, N; Inayama, M; Kakiuchi, S; Muguruma, H; Nakataki, E; Nishikubo, N; Ohtsuka, S; Sone, S; Tomimoto, H; Yano, S	1
Matsumori, Y; Muguruma, H; Nakataki, E; Sone, S; Yano, S; Yoshizumi, M; Zheng, R	1
Benson, K; Booth, B; Chen, YF; Chidambaram, N; Cohen, M; Duan, J; Gobburu, J; Hsieh, LS; Johnson, JR; Leighton, J; Pazdur, R; Sridhara, R; Williams, GM; Zimmerman, P	1
Haddad, RI; Joshi, VA; Lee, JC; Lindeman, NI; Norris, CM; Posner, MR; Wirth, LJ; Zhao, X	1
Benson, AB; Berlin, JD; Coffey, RJ; LaFleur, B; Levy, DE; Morgan-Meadows, SL; Ramanathan, RK; Rothenberg, ML; Washington, MK	1
A'Hern, RP; Box, C; D'Ambrosio, C; Eccles, SA; Harrington, KJ; Kirby, AM; Nutting, CM; Rogers, SJ; Syrigos, KN; Tanay, M	1
Aprile, G; Balzano, G; Bonetto, E; Brandes, AA; Cordio, S; Dell'Oro, S; Di Carlo, V; Fugazza, C; Luppi, G; Milandri, C; Nicoletti, R; Pasetto, L; Passoni, P; Piemonti, L; Reni, M; Zerbi, A	1
Hennemann, B	1
Chen, E; Dancey, J; Hedley, D; Ho, J; Major, P; Moore, MJ; Nicklee, T; Oza, AM; Pond, GR; Siu, LL; Townsley, CA; Tsao, M	1
Demlová, R; Dusek, L; Jarkovský, J; Kiss, I; Kocáková, I; Vyzula, R	1
Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX	1
Leow, CH; Liam, CK; Pang, YK	1
Bianco, AR; Caputo, F; Catalano, G; Ciardiello, F; Colantuoni, G; De Laurentiis, M; De Placido, S; De Vita, F; Diadema, MR; Gridelli, C; Orditura, M; Palmieri, G; Tortora, G; Troiani, T	1
Pérol, M	1
Bièche, I; Blanc, JF; Dugot-Senant, N; Laurendeau, I; Pines, M; Rosenbaum, J; Rullier, A; Taras, D	1
Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F	1
Cohen, EE	1
Laurie, SA; Licitra, L	1
Bang, SI; Choi, YJ; Kim, DK; Kim, JH; Kim, MH; Nam, DH; Nam, SJ; Son, MJ; Song, HS; Yang, JH	1
Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Heseltine, D; Meyerhardt, JA; Ogino, S; Ryan, DP; Zhu, AX	1
Mancuso, A; Sternberg, CN	1
Agelaki, S; Argiraki, A; Christofillakis, Ch; Georgoulias, V; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Souglakos, J; Tselepatiotis, E; Vamvakas, L; Vardakis, N	1
Balak, MN; Chiang, A; Gong, Y; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Ouerfelli, O; Pao, W; Riely, GJ; Somwar, R; Yang, G; Zakowski, MF	1
Boggess, KA; Dees, EC; Dorflinger, LJ; Graham, M; Harris, J; Humes, E; Kelly, H; O'Neil, BH; Spector, NL	1
Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX	1
Barge, A; Bruns, CJ; Conrad, C; Geissler, EK; Guba, M; Ischenko, I; Jauch, KW; Köhl, G; Ryan, AJ; Wedge, SR; Wiegand, U; Yezhelyev, M	1
Cescon, TP; Dennison, SK; Geyer, CE; Jacobs, SA; Raymond, JM; Seeger, J; Swain, SM; Wilson, JW; Wolmark, N	1
Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L	1
Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L	1
Amar, S; Moreno-Aspitia, A; Perez, EA	1
Brand, RE; Carneiro, BA; Fine, E; Khandekar, JD; Knop, RH; Locker, GY; Uhlig, W	1
Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C	1
Ahuja, A; Chan, AT; Hui, EP; Kam, M; King, A; Leung, SF; Lo, YM; Ma, B; Mo, F; Mok, T; To, KF; Zee, B	1
Britten, CD; Gelmon, K; Guo, F; Letrent, SP; Munster, PN; Sharma, A; Tolcher, AW	1
Bukowski, RM; Drabkin, HA; Dutcher, J; Figlin, RA; Flaherty, K; Kabbinavar, FF; McDermott, D; Ryba, S; Scappaticci, FA; Srinivas, S; Vaishampayan, U; Xia, Q	1
Eniu, A	1
Bélanger, K; Eisenhauer, EA; Lee, CW; Petrella, TM; Rao, SC; Savage, KJ; Seymour, L; Synold, TW; Tozer, RG; Wainman, N; Wood, L	1
Carrasco, AT; Chaigneau, L; Extra, JM; Fabbro, M; Floquet, A; Gladieff, L; Goncalves, A; Lhommé, C; Viens, P	1
Gemma, A; Kudoh, S; Matsuda, K; Minegishi, Y; Nara, M; Noro, R; Okano, T; Shibuya, M; Takemura, A; Yoshimura, A	1
Beale, P; Brennscheidt, U; Bugat, R; Clarke, S; Delord, JP; Fettner, SH; Feyereislova, A; Rakhit, A; Van Cutsem, E; Verslype, C	1
Ng, K; Zhu, AX	1
Chen, EX; Chia, S; Colevas, AD; Hotte, SJ; Johnson, C; Pond, GR; Schwarz, JK; Siu, LL; Synold, TW; Tang, PA; Vasist, LS; Winquist, E	1
Comb, MJ; Guo, A; Gygi, SP; Innocenti, G; Kornhauser, J; Lee, KA; MacNeill, J; Mitchell, J; Nardone, J; Polakiewicz, RD; Possemato, A; Rikova, K; Rush, J; Stokes, MP; Villén, J; Wang, Y; Wetzel, R	1
Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P	1
Biagi, JJ; Cripps, C; Eisenhauer, E; Feld, R; Gill, S; Knox, JJ; Major, P; Seymour, L; Synold, TW; Wainman, N	1
Au, GK; Chua, DT; Nicholls, J; Sham, JS; Wei, WI; Wong, MP	1
Doyle, DM; Miller, KD	1
Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T	1
Heinemann, V; Rack, B; Salat, C; Schindlbeck, C; Sommer, H; Walther, J	1
Adam, P; Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Quinkler, M; Ritte, C; Ritter, C; Strasburger, C; Wortmann, S	1
Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E	1
Chua, YJ; Zalcberg, JR	1
Dean-Colomb, W; Esteva, FJ	1
Ang, PC; Arbushites, MC; Aziz, Z; Berger, MS; Casey, MA; Chavez, MA; Chow, LW; Doval, DC; Franco, SX; Gomez, HL; Nag, S; Ng, C; Sledge, GW; Stein, SH	1
Amar, S; Perez, EA; Roy, V	1
Bagattini, S; Bladou, F; Brunelle, S; Esterni, B; Gonçalves, A; Gravis, G; Marcy, M; Salem, N; Viens, P; Walz, J	1
Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP	1
Betit-Yen, K; Gitterman, CO; Lee, G; Luell, S; Prendergast, JS; Skipski, VP; Stock, CC	1
Yano, S	1
Fridman, R; Kondapaka, SB; Reddy, KB	1
Blessing, JA; Homesley, HD; Muggia, FM; Sorosky, J	1
Bours, V; Fillet, G; Jerusalem, G	1
Aiba, K; Horikoshi, N; Kikkawa, N; Kurihara, M; Mitachi, Y; Sakata, Y; Sato, A; Shirouzu, K; Wakui, A	1
Blay, JY; Hermans, C; Judson, I; Rodenhuis, S; Smith, M; van Glabbeke, M; Verweij, J	1
Mitry, E; Rougier, P	1
Nakagawa, K	1
Avallone, A; Budillon, A; Caponigro, F; Comella, G; Comella, P	1
Matsubara, T; Ogasawara, M; Suzuki, H	1
Gildea, JJ; Gulding, KM; Harding, MA; Seraj, MJ; Theodorescu, D	1
Holen, KD; Saltz, LB	1
Aparicio, J; Camps, C; Escudero, P; Feliu, J; García Girón, C; González Barón, M; Mel, JR; Menéndez, D; Rodriguez, MR; Sánchez, JJ	1
Antognoli, S; Baldelli, AM; Barni, S; Battelli, N; Cascinu, S; Catalano, V; Ferraù, F; Giordani, P; Graziano, F; Labianca, R; Maisano, R; Mari, D; Massacesi, C; Pessi, MA; Priolo, D; Rota, S; Santini, D; Siena, S; Silva, RR; Tonini, G; Zaniboni, A	1
Comis, RL; Hudes, GR; LaCreta, F; Litwin, S; O'Dwyer, PJ; Tinsley, P; Walczak, J	1
Carlson, RW; Doroshow, JH; Flam, MS; Lamborn, KR; Malec, M; Odujinrin, OO	1
Grove, W; Holsti, LR; Maasilta, P; Mattson, K; Tammilehto, L	1
Covington, WP; Ho, DH; Krakoff, IH; Legha, SS; Newman, RA	1
Stewart, JA	1
Leiby, JM	1
Comis, RL; Hudes, GR	1
Atassi, G; Brassinne, C; Coune, A; Frühling, J; Laduron, C; Ruysschaert, JM; Sculier, JP	1

Reviews

79 review(s) available for quinazolines and Neoplasm Metastasis

Article	Year
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? International journal of colorectal disease, 2020, Volume: 35, Issue:2 Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Thymine; Time Factors; Trifluridine; Uracil	2020
HER2-positive metastatic breast cancer: a comprehensive review. Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Female; Humans; Immunoconjugates; Neoplasm Metastasis; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab	2021
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer. Best practice & research. Clinical endocrinology & metabolism, 2017, Volume: 31, Issue:3 Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Thyroid Neoplasms	2017
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review . International journal of clinical pharmacology and therapeutics, 2018, Volume: 56, Issue:2 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Trastuzumab; Treatment Outcome	2018
HER2-positive breast cancer: Current and new therapeutic strategies. Breast (Edinburgh, Scotland), 2018, Volume: 39 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab	2018
A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis. Journal of cancer research and clinical oncology, 2019, Volume: 145, Issue:9 Topics: Benzofurans; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Quinazolines; Treatment Outcome	2019
Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. Pancreas, 2013, Volume: 42, Issue:5 Topics: Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2013
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:10 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Maytansine; Neoadjuvant Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2013
Progress of molecular targeted therapies for advanced renal cell carcinoma. BioMed research international, 2013, Volume: 2013 Topics: Carcinoma, Renal Cell; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A	2013
Vandetanib for the treatment of medullary thyroid carcinoma. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Interactions; Drug Labeling; Humans; Neoplasm Metastasis; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms	2014
Icotinib: activity and clinical application in Chinese patients with lung cancer. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials, Phase III as Topic; Crown Ethers; Drug Interactions; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic	2014
[Clinical evaluation of lapatinib therapy in metastatic breast cancer using the Bayes meta-analysis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:3 Topics: Antineoplastic Agents; Bayes Theorem; Breast Neoplasms; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome	2014
A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer. Anti-cancer drugs, 2014, Volume: 25, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiotoxicity; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Liver; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes	2014
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:11 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab	2014
Vandetanib as a potential treatment for breast cancer. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines	2014
Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review. BMC cancer, 2014, Aug-28, Volume: 14 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2014
Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Nov-15, Volume: 71, Issue:22 Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines	2014
[New targeted therapies in breast cancer]. Gynecologie, obstetrique & fertilite, 2014, Volume: 42, Issue:11 Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Lapatinib; Maytansine; Neoadjuvant Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Trastuzumab	2014
HER2-positive metastatic breast cancer: a changing scenario. Critical reviews in oncology/hematology, 2015, Volume: 95, Issue:1 Topics: Ado-Trastuzumab Emtansine; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab	2015
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Anti-cancer drugs, 2015, Volume: 26, Issue:7 Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Treatment Failure	2015
Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2015 Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Early Detection of Cancer; Head and Neck Neoplasms; Humans; Immunotherapy; Meta-Analysis as Topic; Methotrexate; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Papillomavirus Vaccines; Postoperative Care; Precision Medicine; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Therapies, Investigational	2015
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget, 2015, Sep-29, Volume: 6, Issue:29 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2015
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anti-cancer drugs, 2016, Volume: 27, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2016
Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2016, Volume: 34, Issue:7 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab	2016
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Mar-15, Volume: 22, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Discovery; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Research Design; Treatment Outcome; United States; United States Food and Drug Administration	2016
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. BioMed research international, 2016, Volume: 2016 Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines	2016
Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer treatment reviews, 2017, Volume: 55 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Lapatinib; Life Expectancy; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab	2017
Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Sep-15, Volume: 65, Issue:18 Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Food-Drug Interactions; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2	2008
Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab. Clinical breast cancer, 2008, Volume: 8 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2008
Lapatinib and ixabepilone for the treatment of metastatic breast cancer. Pharmacotherapy, 2008, Volume: 28, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Epothilones; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines	2008
New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert review of anticancer therapy, 2009, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Taxoids	2009
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden	2009
Lapatinib for the treatment of HER2-overexpressing breast cancer. Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2	2009
Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs, 2009, Nov-12, Volume: 69, Issue:16 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines	2009
Lapatinib in metastatic breast cancer. Women's health (London, England), 2009, Volume: 5, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab	2009
Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer treatment reviews, 2010, Volume: 36, Issue:5 Topics: Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2010
Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. Expert review of anticancer therapy, 2010, Volume: 10, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Trastuzumab	2010
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review. Sao Paulo medical journal = Revista paulista de medicina, 2009, Volume: 127, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic	2009
Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature. BMC cancer, 2010, Feb-21, Volume: 10 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hemorrhage; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed	2010
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10 Topics: BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Clinical Trials, Phase II as Topic; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Histone Chaperones; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Neoplasm Staging; Nuclear Proteins; Quinazolines; RNA, Messenger	2010
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma. Current cancer drug targets, 2010, Volume: 10, Issue:6 Topics: Animals; Apoptosis; Carcinoma; Chemotherapy, Adjuvant; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines	2010
Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:6 Topics: Adenocarcinoma; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Time Factors	2010
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. Drugs, 2010, Jul-30, Volume: 70, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Triazoles	2010
Challenges of drug resistance in the management of pancreatic cancer. Expert review of anticancer therapy, 2010, Volume: 10, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment	2010
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:6 Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles	2011
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2011
Treatment of non-small-cell lung cancer with erlotinib or gefitinib. The New England journal of medicine, 2011, Mar-10, Volume: 364, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2011
Metastatic pancreatic cancer: old drugs, new paradigms. Current opinion in oncology, 2011, Volume: 23, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines	2011
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagnostic cytopathology, 2011, Volume: 39, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins	2011
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2012
Target therapy in elderly breast cancer patients. Critical reviews in oncology/hematology, 2012, Volume: 83, Issue:3 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A	2012
Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World journal of gastroenterology, 2012, Feb-28, Volume: 18, Issue:8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib	2012
Lapatinib for advanced or metastatic breast cancer. The oncologist, 2012, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines	2012
Vandetanib: in medullary thyroid cancer. Drugs, 2012, Jul-09, Volume: 72, Issue:10 Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Molecular Structure; Neoplasm Metastasis; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Thyroid Neoplasms	2012
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). Current medical research and opinion, 2012, Volume: 28, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles	2012
Vandetanib: a guide to its use in advanced medullary thyroid cancer. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2012, Dec-01, Volume: 26, Issue:6 Topics: Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms	2012
Advances in the treatment of metastatic colorectal cancer. Clinical colorectal cancer, 2001, Volume: 1, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Uracil	2001
The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 1 Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2003
[Angiogenesis and metastasis in colorectal cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7 Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Metastasis; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A	2003
The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer. Clinical lung cancer, 2003, Volume: 5 Suppl 1 Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Quinazolines; Signal Transduction; Tumor Cells, Cultured	2003
Adjuvant systemic therapies in early-stage non-small-cell lung cancer. Clinical lung cancer, 2003, Volume: 5 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis	2003
New developments in systemic chemotherapy in advanced colorectal cancer. Scandinavian journal of gastroenterology. Supplement, 2003, Issue:239 Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil	2003
[Palliative chemotherapy of head and neck cancer: present status and future development]. Laryngo- rhino- otologie, 2006, Volume: 85, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine	2006
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome	2006
Systemic therapy in the palliative management of advanced salivary gland cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab	2006
New treatment approaches in metastatic renal cell carcinoma. Current opinion in urology, 2006, Volume: 16, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2006
Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast cancer research and treatment, 2008, Volume: 109, Issue:1 Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Lapatinib; Medical Oncology; Models, Biological; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab	2008
Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2007, Volume: 12 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Heart Diseases; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A	2007
Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Critical reviews in oncology/hematology, 2008, Volume: 65, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Mutation; Neoplasm Metastasis; Panitumumab; Quinazolines	2008
[Metastatic breast cancer--new methods of treatment]. MMW Fortschritte der Medizin, 2008, Jan-17, Volume: 150, Issue:1-2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Histocytochemistry; Humans; Lapatinib; Neoplasm Metastasis; Osteonecrosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Risk Factors; Signal Transduction; Time Factors; Trastuzumab	2008
Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert review of anticancer therapy, 2008, Volume: 8, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab	2008
Pancreatic cancer--is the wall crumbling? Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis	2008
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Seminars in oncology, 2008, Volume: 35, Issue:2 Suppl 2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine	2008
Treatment of metastatic breast cancer: looking towards the future. Breast cancer research and treatment, 2009, Volume: 114, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome	2009
[Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer]. Revue medicale de Liege, 1998, Volume: 53, Issue:6 Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Hospitalization; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Quinazolines; Rectal Neoplasms; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors	1998
Current treatment options for advanced colorectal cancer. Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10 Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes	2000
[Tyrosine kinase inhibitors--solid cancers]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Enzyme Inhibitors; Gefitinib; Humans; Neoplasm Metastasis; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2001
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy. Anti-cancer drugs, 2001, Volume: 12, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Rectal Neoplasms; Thiophenes	2001
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. The Lancet. Oncology, 2001, Volume: 2, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Trimetrexate; Uracil	2001

Trials

173 trial(s) available for quinazolines and Neoplasm Metastasis

Article	Year
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 11-01, Volume: 25, Issue:21 Topics: Adolescent; Adult; Child; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperidines; Progression-Free Survival; Proto-Oncogene Proteins c-kit; Quality of Life; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Succinate Dehydrogenase; Young Adult	2019
Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS). Pediatric blood & cancer, 2019, Volume: 66, Issue:12 Topics: Adolescent; Antineoplastic Agents; Child; Female; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Prognosis; Quinazolines; Sarcoma, Alveolar Soft Part; Survival Rate	2019
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast cancer research : BCR, 2017, 05-02, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-1	2017
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast cancer research and treatment, 2017, Volume: 164, Issue:3 Topics: Adult; Aged; Antigens, Neoplasm; Breast Neoplasms; Carbonic Anhydrase IX; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Trastuzumab; Treatment Outcome; Young Adult	2017
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. The Lancet. Oncology, 2017, Volume: 18, Issue:6 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Chemotherapy-Induced Febrile Neutropenia; Diarrhea; Early Termination of Clinical Trials; Female; Hemorrhage; Humans; Lapatinib; Male; Maytansine; Middle Aged; Neoplasm Metastasis; Neutropenia; Practice Patterns, Physicians'; Quinazolines; Receptor, ErbB-2; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab	2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Oct-01, Volume: 28, Issue:10 Topics: Administration, Intravenous; Administration, Oral; Afatinib; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Disease-Free Survival; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2017
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Japanese journal of clinical oncology, 2018, Mar-01, Volume: 48, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Demography; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Vinblastine; Vinorelbine	2018
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. International journal of cancer, 2018, 12-15, Volume: 143, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Republic of Korea; Survival Analysis	2018
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. The oncologist, 2019, Volume: 24, Issue:5 Topics: Adult; Aged; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Quinazolines; Tegafur; Thiophenes	2019
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positi International journal of cancer, 2019, 09-15, Volume: 145, Issue:6 Topics: Adult; Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Exons; Female; Gene Expression; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2	2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. The oncologist, 2019, Volume: 24, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A	2019
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU international, 2013, Volume: 111, Issue:8 Topics: Adenocarcinoma; Administration, Oral; Aged; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2013
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Breast Neoplasms; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lymphopenia; Middle Aged; Neoplasm Metastasis; Nitrogen Mustard Compounds; Quinazolines; Severity of Illness Index	2013
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. British journal of cancer, 2013, Apr-02, Volume: 108, Issue:6 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2013
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome	2013
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:6 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Outcome	2013
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8 Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3	2013
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. The oncologist, 2013, Volume: 18, Issue:6 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab	2013
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral oncology, 2013, Volume: 49, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Taxoids	2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Aug-01, Volume: 19, Issue:15 Topics: Adolescent; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Humans; Multiple Endocrine Neoplasia Type 2b; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms	2013
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Denmark; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A	2013
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Investigational new drugs, 2013, Volume: 31, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factor 2; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult	2013
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-20, Volume: 31, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pemetrexed; Quinazolines	2013
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Trastuzumab; Young Adult	2013
Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial. Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Time Factors; Turkey; Vinblastine; Vinorelbine	2013
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperidines; Platinum Compounds; Quinazolines; Vascular Endothelial Growth Factor A	2013
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. Cancer, 2013, Dec-01, Volume: 119, Issue:23 Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Fluorouracil; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha	2013
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. British journal of cancer, 2013, Nov-26, Volume: 109, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Disease Progression; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines	2013
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Vinblastine	2014
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast cancer research and treatment, 2014, Volume: 143, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine	2014
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:5 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome	2014
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future oncology (London, England), 2014, Volume: 10, Issue:2 Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Treatment Outcome	2014
Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Microscopy, Fluorescence; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Quinazolines	2014
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Treatment Outcome	2014
LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. Future oncology (London, England), 2014, Volume: 10, Issue:4 Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Treatment Outcome	2014
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. Oncology research, 2013, Volume: 21, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome	2013
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer immunology, immunotherapy : CII, 2014, Volume: 63, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Oligonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9; Treatment Outcome	2014
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate	2014
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC cancer, 2014, Jun-28, Volume: 14 Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck	2014
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome	2014
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. British journal of cancer, 2014, Nov-25, Volume: 111, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines	2014
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group. Anticancer research, 2014, Volume: 34, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Quinazolines; Risk Factors; Taxoids; Treatment Outcome	2014
Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome	2014
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-10, Volume: 32, Issue:32 Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome	2014
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study. Journal of the Egyptian National Cancer Institute, 2014, Volume: 26, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2014
Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer. Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Radiography; Response Evaluation Criteria in Solid Tumors; Vinblastine; Vinorelbine	2014
Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jun-15, Volume: 21, Issue:12 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retreatment; Trastuzumab	2015
Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation. Journal of cancer research and therapeutics, 2014, Volume: 10 Suppl Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis	2014
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult	2015
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. Clinical lung cancer, 2015, Volume: 16, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Thymidylate Synthase; Treatment Outcome	2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:5 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2015
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer. International journal of clinical oncology, 2015, Volume: 20, Issue:6 Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Female; Hemoglobins; Humans; Japan; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Survival Rate	2015
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition Urologia internationalis, 2016, Volume: 96, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium	2016
A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:3 Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines	2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-20, Volume: 33, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2015
A phase I study of volasertib combined with afatinib, in advanced solid tumors. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:4 Topics: Administration, Oral; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Neutropenia; Protein Kinase Inhibitors; Pteridines; Quinazolines; Severity of Illness Index; Thrombocytopenia	2015
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Archives of gynecology and obstetrics, 2016, Volume: 293, Issue:2 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Phenotype; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2016
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. The Prostate, 2016, Feb-15, Volume: 76, Issue:3 Topics: Academic Medical Centers; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Chicago; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quinazolines	2016
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:5 Topics: Aged; Benzodioxoles; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Quinazolines; Vascular Endothelial Growth Factor A	2016
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Rand Clinical lung cancer, 2016, Volume: 17, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Female; Gefitinib; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Smoking; Survival Analysis; Treatment Outcome; Young Adult	2016
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:3 Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine	2016
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016, Volume: 11, Issue:3 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Treatment Outcome	2016
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erloti BMC cancer, 2016, Feb-24, Volume: 16 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome	2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:8 Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab	2016
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. Breast cancer research and treatment, 2016, Volume: 160, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Retreatment; Signal Transduction; Treatment Outcome; Triazoles	2016
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer research and treatment, 2017, Volume: 49, Issue:4 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Simvastatin; Survival Analysis; Treatment Outcome	2017
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. British journal of cancer, 2008, Sep-02, Volume: 99, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis	2008
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-01, Volume: 14, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Protein Binding; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2008
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. The oncologist, 2008, Volume: 13, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Approval; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration; Young Adult	2008
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines	2009
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Placebos; Quinazolines; Receptor, ErbB-2; Retrospective Studies	2008
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-01, Volume: 14, Issue:21 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines	2008
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-01, Volume: 27, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines	2009
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. American journal of clinical oncology, 2009, Volume: 32, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Analysis; Testosterone; Treatment Outcome	2009
Lapatinib for the treatment of HER2-overexpressing breast cancer. Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2	2009
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU international, 2010, Volume: 105, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urologic Neoplasms; Urothelium	2010
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aged; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Protein Kinase Inhibitors; Quinazolines	2010
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Current medical research and opinion, 2010, Volume: 26, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Health Status; Humans; Lapatinib; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quinazolines; Receptor, ErbB-2	2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-01, Volume: 28, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Function, Left	2010
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival; Treatment Outcome	2011
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-15, Volume: 16, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles	2010
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-15, Volume: 16, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome	2010
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Codon; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Young Adult	2010
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tomography, Emission-Computed; Treatment Outcome	2011
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome	2011
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. American journal of clinical oncology, 2012, Volume: 35, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate	2012
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Investigational new drugs, 2012, Volume: 30, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Benzodioxoles; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Stomach Neoplasms	2012
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Investigational new drugs, 2012, Volume: 30, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2	2012
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational new drugs, 2012, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein	2012
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:12 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Metastasis; Quality of Life; Quinazolines; Receptor, ErbB-2; Surveys and Questionnaires; Trastuzumab; Treatment Outcome	2011
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Colorectal Neoplasms; Demography; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Treatment Outcome	2012
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clinical breast cancer, 2011, Volume: 11, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; New York City; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome	2011
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-20, Volume: 29, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Placebos; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Receptors, Growth Factor; Survival Analysis	2011
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. British journal of cancer, 2011, Sep-06, Volume: 105, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Protein Kinase Inhibitors; Quinazolines	2011
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Quinazolines; Survival Analysis; Treatment Outcome	2012
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-10, Volume: 30, Issue:2 Topics: Carcinoma, Neuroendocrine; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Placebos; Quinazolines; Thyroid Neoplasms	2012
A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast cancer research and treatment, 2012, Volume: 131, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome	2012
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:10 Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Placebos; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk	2012
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology, 2012, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines	2012
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast cancer research and treatment, 2012, Volume: 134, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2012
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PloS one, 2012, Volume: 7, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Pulmonary Embolism; Quinazolines; Treatment Outcome	2012
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast cancer research and treatment, 2012, Volume: 133, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles	2012
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast cancer research and treatment, 2012, Volume: 133, Issue:3 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2012
HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology, 2012, Volume: 82, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate	2012
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral oncology, 2012, Volume: 48, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Gefitinib; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin	2012
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clinical breast cancer, 2012, Volume: 12, Issue:3 Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-2	2012
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-10, Volume: 30, Issue:26 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotoxins; Lapatinib; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab	2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PloS one, 2012, Volume: 7, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factors	2012
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution	2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast cancer research and treatment, 2012, Volume: 134, Issue:3 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome	2012
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. PloS one, 2012, Volume: 7, Issue:7 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Trastuzumab	2012
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-10, Volume: 30, Issue:29 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Pyridines; Quinazolines; Survival Analysis	2012
Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine, 2012, Nov-08, Volume: 367, Issue:19 Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult	2012
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Investigational new drugs, 2013, Volume: 31, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; T-Lymphocytes; Treatment Outcome	2013
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 79, Issue:3 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Proteins; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proteomics; Quinazolines; Survival Analysis	2013
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. British journal of cancer, 2013, Feb-19, Volume: 108, Issue:3 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; International Agencies; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Quinazolines; Salvage Therapy; Survival Rate; Young Adult	2013
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer medicine, 2012, Volume: 1, Issue:2 Topics: 3' Untranslated Regions; Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzodioxoles; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Insulin-Like Growth Factor Binding Protein 2; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Quinazolines; Receptors, Cell Surface; src-Family Kinases	2012
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Investigational new drugs, 2013, Volume: 31, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Contrast Media; Demography; Disease Progression; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome	2013
Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics. Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Health Care Costs; Humans; Length of Stay; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Norway; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Thiophenes; Treatment Outcome	2002
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Illinois; Immunohistochemistry; Intubation, Gastrointestinal; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Treatment Outcome	2003
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Cycle Proteins; Cell Division; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; Cytoskeletal Proteins; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Trans-Activators; Tumor Suppressor Proteins	2003
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-15, Volume: 21, Issue:14 Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Preoperative Care; Probability; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome	2003
A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2). Clinical breast cancer, 2003, Volume: 4, Issue:2 Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Infusions, Intravenous; Neoplasm Metastasis; Quinazolines; Trastuzumab; Treatment Outcome	2003
Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Anti-cancer drugs, 2003, Volume: 14, Issue:7 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Female; Folic Acid Antagonists; Humans; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Predictive Value of Tests; Quinazolines; Thiophenes; Transaminases	2003
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome	2003
Adjuvant systemic therapies in early-stage non-small-cell lung cancer. Clinical lung cancer, 2003, Volume: 5 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis	2003
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines	2004
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-01, Volume: 10, Issue:5 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Glucuronides; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Patient Selection; Quinazolines; Thiophenes; Vomiting	2004
Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. Medical oncology (Northwood, London, England), 2004, Volume: 21, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome	2004
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-01, Volume: 11, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Bridged-Ring Compounds; Diarrhea; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Piperidines; Quinazolines; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-10, Volume: 23, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Quinazolines; Receptor, ErbB-2; Safety; Treatment Outcome	2005
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Recurrence; Tomography, X-Ray Computed	2006
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18 Topics: Adolescent; Adult; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Failure; Treatment Outcome; United States; United States Food and Drug Administration	2005
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pyrazoles; Quinazolines; Sulfonamides	2005
ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Gefitinib; Humans; Neoplasm Metastasis; Patient Selection; Quinazolines; Receptor, ErbB-2; Trastuzumab	2003
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis	2005
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. British journal of cancer, 2006, Mar-13, Volume: 94, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Survival Analysis	2006
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Salvage Therapy; Survival Analysis; Thiophenes	2006
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. British journal of cancer, 2006, Apr-24, Volume: 94, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Recurrence; Risk Factors; Signal Transduction; Survival Rate; Treatment Outcome	2006
Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer. Neoplasma, 2006, Volume: 53, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome	2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Apr-20, Volume: 24, Issue:12 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis	2006
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. British journal of cancer, 2006, Jun-05, Volume: 94, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Taxoids; Treatment Outcome	2006
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Thiophenes	2006
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clinical colorectal cancer, 2006, Volume: 6, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines	2006
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 55, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Smoking; Survival Analysis; Taxoids	2007
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines	2007
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Investigational new drugs, 2007, Volume: 25, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinazolines; Taxoids; Treatment Outcome	2007
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer, 2007, Aug-15, Volume: 110, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Disease Progression; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Dropouts; Quinazolines; Time Factors; Treatment Outcome	2007
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology, 2006, Volume: 71, Issue:3-4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids	2006
Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma. Cancer investigation, 2007, Volume: 25, Issue:5 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines	2007
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:1 Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; DNA, Viral; ErbB Receptors; Female; Gefitinib; Herpesvirus 4, Human; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Radiography; Survival	2008
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:1 Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Half-Life; Humans; Liver Function Tests; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tandem Mass Spectrometry	2008
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-10, Volume: 25, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Placebos; Quinazolines; Treatment Outcome	2007
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Delivery Systems; Eye Neoplasms; Female; Humans; Kinesins; Male; Melanoma; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin Neoplasms; Treatment Outcome	2008
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic oncology, 2008, Volume: 108, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Uterine Cervical Neoplasms	2008
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:2 Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome	2008
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Gene Expression; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Kinesins; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Quinazolines; Treatment Outcome	2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast cancer research and treatment, 2008, Volume: 112, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Trastuzumab	2008
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Disease Progression; Female; Gene Expression; Humans; Infusions, Intravenous; Kinesins; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome	2008
Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head & neck, 2008, Volume: 30, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome	2008
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Taxoids; Treatment Outcome	2008
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:6 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Routes; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Salvage Therapy; Treatment Outcome	2008
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jun-20, Volume: 26, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2	2008
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:9 Topics: Adenocarcinoma; Administration, Oral; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome	2008
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast cancer research and treatment, 2009, Volume: 115, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Taxoids	2009
Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group. Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Platinum Compounds; Quinazolines; Thiophenes; Thymidylate Synthase	1998
Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group. Anti-cancer drugs, 1999, Volume: 10, Issue:8 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Thiophenes; Thymidylate Synthase; Time Factors; Treatment Outcome	1999
Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anti-cancer drugs, 1999, Volume: 10, Issue:10 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinazolines; Sarcoma; Soft Tissue Neoplasms; Thiophenes; Thrombocytopenia; Treatment Outcome	1999
Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:9 Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Sex Factors; Survival Analysis; Thiophenes; Treatment Outcome	2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Italy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Thiophenes; Treatment Outcome	2002
Pharmacokinetic study of trimetrexate in combination with cisplatin. Cancer research, 1991, Jun-15, Volume: 51, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein Binding; Quinazolines; Trimetrexate	1991
Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group. Investigational new drugs, 1990, Volume: 8, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents; Drug Evaluation; Drugs, Investigational; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Trimetrexate	1990

Other Studies

200 other study(ies) available for quinazolines and Neoplasm Metastasis

Article	Year
Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain. Scientific reports, 2021, 10-15, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Carriers; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2	2021
Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 01-04, Volume: 119, Issue:1 Topics: Animals; Antineoplastic Agents, Immunological; Brain Neoplasms; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms, Experimental; Neural Stem Cells; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays	2022
Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process. Oncology, 2023, Volume: 101, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Trastuzumab	2023
Fruquintinib and its use in the treatment of metastatic colorectal cancer. Future oncology (London, England), 2019, Volume: 15, Issue:22 Topics: Angiogenesis Inhibitors; Benzofurans; Cell Proliferation; China; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2019
G9a and histone deacetylases are crucial for Snail2-mediated E-cadherin repression and metastasis in hepatocellular carcinoma. Cancer science, 2019, Volume: 110, Issue:11 Topics: Acetylation; Animals; Azepines; Cadherins; Carcinoma, Hepatocellular; Cell Movement; Disease Progression; Down-Regulation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Histocompatibility Antigens; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone-Lysine N-Methyltransferase; Humans; Hydroxamic Acids; Liver; Liver Neoplasms; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Quinazolines; Snail Family Transcription Factors; Transcription, Genetic; Transforming Growth Factor beta	2019
Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:9 Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines	2019
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study. Targeted oncology, 2019, Volume: 14, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Quinazolines; Registries; Retrospective Studies; Survival Rate	2019
Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. Oncogene, 2020, Volume: 39, Issue:12 Topics: Animals; Aurora Kinase B; Breast Neoplasms; Carcinoma, Ductal; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Neoplasm Invasiveness; Neoplasm Metastasis; Octamer Transcription Factor-3; Organophosphates; Phosphorylation; Protein Kinase Inhibitors; Protein Stability; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Triple Negative Breast Neoplasms	2020
Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer. Tumori, 2020, Volume: 106, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Neoplasm Metastasis; Progression-Free Survival; Quality-Adjusted Life Years; Quinazolines	2020
The PI3Kα inhibitor DFX24 suppresses tumor growth and metastasis in non-small cell lung cancer via ERK inhibition and EPHB6 reactivation. Pharmacological research, 2020, Volume: 160 Topics: Antineoplastic Agents; Apoptosis; Benzene Derivatives; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Movement; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mitochondria; Morpholines; Neoplasm Metastasis; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Eph Family; Sulfonamides; Xenograft Model Antitumor Assays	2020
2,4-Diamino-Quinazoline, a Wnt Signaling Inhibitor, Suppresses Gastric Cancer Progression and Metastasis. International journal of molecular sciences, 2020, Aug-17, Volume: 21, Issue:16 Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Axin Protein; Cell Line; Cell Line, Tumor; Cells, Cultured; Female; Humans; Lymphoid Enhancer-Binding Factor 1; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins c-myc; Quinazolines; Receptors, G-Protein-Coupled; Stomach Neoplasms; Wnt Signaling Pathway	2020
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China. BMC cancer, 2020, Oct-13, Volume: 20, Issue:1 Topics: Benzofurans; China; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Neoplasm Metastasis; Quinazolines	2020
Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer. Clinical colorectal cancer, 2021, Volume: 20, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada; Colorectal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Thiophenes; Treatment Outcome	2021
A novel anthraquinone‑quinazoline hybrid 7B blocks breast cancer metastasis and EMT via targeting EGFR and Rac1. International journal of oncology, 2021, Volume: 58, Issue:5 Topics: Anthraquinones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Models, Molecular; Molecular Docking Simulation; Neoplasm Metastasis; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction; Triple Negative Breast Neoplasms	2021
Neratinib: an option for HER2-positive metastatic breast cancer. Clinical advances in hematology & oncology : H&O, 2020, Volume: 18 Suppl 15, Issue:9 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Disease Management; Female; Fulvestrant; Humans; Neoplasm Metastasis; Oxazoles; Pyridines; Quality of Life; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2020
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy. JCI insight, 2021, 09-22, Volume: 6, Issue:18 Topics: Animals; Antineoplastic Agents, Immunological; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelium; ErbB Receptors; Female; Humans; Indazoles; Lapatinib; Mammary Glands, Animal; Mice, Transgenic; Neoplasm Metastasis; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Signal Transduction; Sulfonamides; Trastuzumab; Up-Regulation	2021
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 108 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; ErbB Receptors; Exons; Female; Humans; INDEL Mutation; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2017
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA oncology, 2017, Nov-09, Volume: 3, Issue:11 Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome	2017
Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. International journal of molecular sciences, 2017, 07-29, Volume: 18, Issue:8 Topics: Breast Neoplasms; Cell Communication; Cell Line, Tumor; Coculture Techniques; ErbB Receptors; Female; Gefitinib; Humans; Mesenchymal Stem Cells; Monocytes; Neoplasm Metastasis; Neoplasm Proteins; Osteoclasts; Quinazolines; Signal Transduction	2017
Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours). Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jul-01, Volume: 28, Issue:suppl_4 Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Metastasis; Nivolumab; Quinazolines; Ramucirumab; Taxoids	2017
Murine breast cancer mastectomy model that predicts patient outcomes for drug development. The Journal of surgical research, 2017, Volume: 219 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Luminescent Measurements; Lung; Lung Neoplasms; Mammary Neoplasms, Experimental; Mastectomy, Radical; Mice, Inbred BALB C; Neoplasm Metastasis; Quinazolines	2017
Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation? Cancer biology & therapy, 2017, Dec-02, Volume: 18, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma	2017
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B. Clinical endocrinology, 2018, Volume: 88, Issue:5 Topics: Adult; Carcinoma, Neuroendocrine; Female; Humans; Multiple Endocrine Neoplasia Type 2a; Mutation, Missense; Neoplasm Metastasis; Piperidines; Pregnancy; Quinazolines; Thyroid Neoplasms; Young Adult	2018
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report. BMC cancer, 2018, 02-20, Volume: 18, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Capecitabine; Diagnostic Imaging; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Male; Meningeal Carcinomatosis; Multimodal Imaging; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome	2018
Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival. Asia-Pacific journal of clinical oncology, 2018, Volume: 14 Suppl 1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Exons; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Survival Analysis; Time Factors	2018
Transcriptional repressor Kaiso promotes epithelial to mesenchymal transition and metastasis in prostate cancer through direct regulation of miR-200c. Cancer letters, 2018, 09-01, Volume: 431 Topics: Animals; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Quinazolines; Transcription Factors	2018
Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. Cell death & disease, 2018, 06-07, Volume: 9, Issue:6 Topics: Adenine; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class Ia Phosphatidylinositol 3-Kinase; Disease Progression; Enzyme Activation; Female; Humans; Macrophages; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Staging; PTEN Phosphohydrolase; Quinazolines	2018
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib. Journal of hematology & oncology, 2018, 06-20, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Benzodioxoles; Disease Models, Animal; Drug Carriers; Enzyme Inhibitors; Head and Neck Neoplasms; Mice; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Quinazolines; Snail Family Transcription Factors; src-Family Kinases; Vimentin	2018
Fluoxetine Inhibits DNA Repair and NF-ĸB-modulated Metastatic Potential in Non-small Cell Lung Cancer. Anticancer research, 2018, Volume: 38, Issue:9 Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; DNA Repair; Fluoxetine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Metastasis; NF-kappa B; Phenyl Ethers; Quinazolines; Signal Transduction	2018
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations. Clinical lung cancer, 2019, Volume: 20, Issue:1 Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis	2019
Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report. BMC cancer, 2019, Feb-08, Volume: 19, Issue:1 Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Alleles; Amino Acid Substitution; Aniline Compounds; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Combined Modality Therapy; Crown Ethers; ErbB Receptors; Humans; Magnetic Resonance Imaging; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Tomography, X-Ray Computed; Treatment Outcome	2019
Sotrastaurin attenuates the stemness of gastric cancer cells by targeting PKCδ. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 117 Topics: Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Neoplastic Stem Cells; Protein Kinase C-delta; Pyrroles; Quinazolines; Stomach Neoplasms	2019
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Dosage; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Regression Analysis; ROC Curve	2013
Erlotinib in the treatment of patients with multiple metastases from non-small cell lung cancer: clinical case selection for optimal response. Clinical oncology (Royal College of Radiologists (Great Britain)), 2013, Volume: 25, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines	2013
KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Codon; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Randomized Controlled Trials as Topic; ras Proteins; Retrospective Studies; Treatment Outcome	2013
Radiological response of brain metastases to novel tyrosine kinase inhibitor lapatinib. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:9 Topics: Brain Neoplasms; Female; Humans; Lapatinib; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2013
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers? Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate	2013
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Investigational new drugs, 2013, Volume: 31, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines	2013
Evodiamine induces apoptosis and inhibits metastasis in MDA‑MB-231 human breast cancer cells in vitro and in vivo. Oncology reports, 2013, Volume: 30, Issue:2 Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Humans; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptors, Urokinase Plasminogen Activator; Resting Phase, Cell Cycle; Urokinase-Type Plasminogen Activator	2013
[A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2013, Volume: 16, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Drug Therapy; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2013
Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:7 Topics: Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Quinazolines	2013
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma. JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome	2013
Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells. Oncology reports, 2013, Volume: 30, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Cell Line, Tumor; Cell Proliferation; Chemotaxis; Diphtheria Toxin; ErbB Receptors; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-4; RNA, Messenger; Thyroid Neoplasms; Tyrphostins	2013
Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice. Anti-cancer drugs, 2013, Volume: 24, Issue:9 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Clinical Trials, Phase I as Topic; Cytochrome P-450 CYP3A; Docetaxel; Doxorubicin; Drug Interactions; Female; Half-Life; Humans; Intestine, Small; Lapatinib; Membrane Transport Modulators; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Quinazolines; Taxoids; Tissue Distribution; Topoisomerase II Inhibitors; Tubulin Modulators	2013
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer discovery, 2013, Volume: 3, Issue:11 Topics: Adult; Exome; Female; Humans; Lapatinib; Li-Fraumeni Syndrome; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured	2013
LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling. Breast cancer research : BCR, 2013, Volume: 15, Issue:4 Topics: Acinar Cells; Amino Acid Oxidoreductases; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Morphogenesis; Neoplasm Metastasis; Phenotype; Prognosis; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Signal Transduction	2013
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC cancer, 2013, Oct-02, Volume: 13 Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Follow-Up Studies; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Naphthalenes; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Prognosis; Pyrimidinones; Quinazolines; Sirtuin 1	2013
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer. PloS one, 2013, Volume: 8, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2013
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Feb-01, Volume: 20, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles	2014
[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:7 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab	2013
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate	2014
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome	2014
The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. International journal of cancer, 2014, Jun-01, Volume: 134, Issue:11 Topics: Acetylation; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Histone Deacetylase 1; Humans; Immunoenzyme Techniques; Immunoprecipitation; Ku Autoantigen; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Neoplasm Metastasis; Phosphatidylinositol 3-Kinase; Phosphorylation; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, IGF Type 1; Tumor Cells, Cultured	2014
Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab. Cancer biology & therapy, 2014, Volume: 15, Issue:4 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult	2014
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Postmenopause; Premenopause; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Sunitinib; Survival Rate; Trastuzumab; Turkey; Young Adult	2014
EGFR gene mutations in patients with adenosquamous lung carcinoma. Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Poland; Polymerase Chain Reaction; Quinazolines; Remission Induction; Smoking	2014
Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO). Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:4 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Folic Acid Antagonists; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Quinazolines; Retrospective Studies; Salvage Therapy; Tegafur; Thiophenes; Treatment Outcome; Young Adult	2014
Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. Journal of immunotherapy (Hagerstown, Md. : 1997), 2014, Volume: 37, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Erlotinib Hydrochloride; Female; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome	2014
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate	2014
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. Cancer biology & therapy, 2014, Volume: 15, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; ErbB Receptors; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2	2014
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. Clinical lung cancer, 2014, Volume: 15, Issue:4 Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment	2014
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib Breast cancer research : BCR, 2014, Jul-24, Volume: 16, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Metastasis; Odds Ratio; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2014
Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:10 Topics: ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Metastasis; Quinazolines	2014
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Intensive Care Units; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Respiration, Artificial; Tomography, X-Ray Computed; Treatment Outcome	2014
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression. European journal of clinical investigation, 2014, Volume: 44, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome	2014
Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell reports, 2014, Sep-11, Volume: 8, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Surface Extensions; Chick Embryo; Cortactin; Female; Humans; Lung Neoplasms; Matrix Metalloproteinase 14; Mice; Mice, Nude; Neoplasm Metastasis; Neoplastic Stem Cells; Phosphate-Binding Proteins; Phosphoproteins; Protein Kinase Inhibitors; Quinazolines; Transcellular Cell Migration	2014
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. Clinical lung cancer, 2014, Volume: 15, Issue:6 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome	2014
Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report. Journal of medical case reports, 2014, Oct-09, Volume: 8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Cysts; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Pneumothorax; Protein Kinase Inhibitors; Quinazolines; Rupture, Spontaneous	2014
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15 Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cytoskeletal Proteins; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome	2016
Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer. Chinese journal of cancer, 2015, Volume: 34, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Stevens-Johnson Syndrome	2015
Cancer-specific chemoprevention and anti-metastatic potentials of Rheum emodi rhizome ethyl acetate extracts and identification of active principles through HPLC and GC-MS analysis. Pakistan journal of pharmaceutical sciences, 2015, Volume: 28, Issue:1 Topics: Acetates; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Chromatography, High Pressure Liquid; Cyclopropanes; Dose-Response Relationship, Drug; Gas Chromatography-Mass Spectrometry; Humans; Inhibitory Concentration 50; Neoplasm Invasiveness; Neoplasm Metastasis; Phytotherapy; Plants, Medicinal; Polyphenols; Quinazolines; Rheum; Rhizome; Solvents; Time Factors	2015
The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasm Metastasis; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Tumor Suppressor Proteins	2015
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. Journal of translational medicine, 2015, Jan-27, Volume: 13 Topics: Albumins; Apoptosis; Aurora Kinase B; Cell Line, Tumor; Cell Movement; Cell Nucleus Shape; Cell Proliferation; Cell Shape; Cell Survival; Drug Resistance, Neoplasm; Extracellular Space; Humans; Lactic Acid; Melanoma; Mitosis; Necrosis; Neoplasm Metastasis; Organophosphates; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines	2015
Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation. Oncogene, 2015, Oct-08, Volume: 34, Issue:41 Topics: Animals; Antineoplastic Agents; Aptamers, Nucleotide; Cell Line, Tumor; Cell Membrane Permeability; Drug Carriers; Female; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Protein c-ets-1; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays	2015
Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget, 2015, Apr-10, Volume: 6, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Young Adult	2015
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient. The European respiratory journal, 2015, Volume: 46, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome	2015
Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Retreatment; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult	2015
DW-F5: A novel formulation against malignant melanoma from Wrightia tinctoria. Scientific reports, 2015, Jun-10, Volume: 5 Topics: Animals; Antineoplastic Agents, Phytogenic; Apocynaceae; Apoptosis; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Humans; Melanoma; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Plant Extracts; Plant Leaves; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2015
Lapatinib-based therapy for women with advanced/metastatic HER2 positive breast cancer. Experimental oncology, 2015, Volume: 37, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Young Adult	2015
Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. Clinical drug investigation, 2015, Volume: 35, Issue:8 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Canada; Capecitabine; Delivery of Health Care; Female; Health Care Costs; Humans; Lapatinib; Maytansine; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab	2015
Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. Cancer biology & therapy, 2015, Volume: 16, Issue:10 Topics: Afatinib; Carcinoma, Large Cell; Cell Differentiation; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Quinazolines	2015
Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report. Future oncology (London, England), 2015, Volume: 11, Issue:15 Suppl Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Fatal Outcome; Female; Furans; Humans; Ketones; Lapatinib; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retreatment; Trastuzumab	2015
Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study. PloS one, 2015, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Israel; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate; Trastuzumab	2015
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nature communications, 2015, Nov-04, Volume: 6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab	2015
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment. Medicine, 2015, Volume: 94, Issue:45 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperidines; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Thyroid Neoplasms	2015
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. International journal of cancer, 2016, May-15, Volume: 138, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Models, Animal; Female; Gene Expression; Humans; MAP Kinase Signaling System; Mice; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Estrogen; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Tumor Burden; Xenograft Model Antitumor Assays	2016
[PTEN loss correlates withthe clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance]. Zhonghua yi xue za zhi, 2015, Jul-28, Volume: 95, Issue:28 Topics: Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Lapatinib; Neoplasm Metastasis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2015
[Combination of lapatinib with chlorogenic acid inhibits breast cancer metastasis by suppressing macrophage M2 polarization]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2015, Volume: 44, Issue:5 Topics: Animals; Chlorogenic Acid; Female; Lapatinib; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Quinazolines	2015
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. Journal of medical economics, 2016, Volume: 19, Issue:6 Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles	2016
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast cancer research and treatment, 2016, Volume: 155, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Trastuzumab	2016
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 08-01, Volume: 22, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Female; Gefitinib; Gene Amplification; Gene Expression; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Squamous Cell Carcinoma of Head and Neck	2016
Colorectal Cancer Yields to Dual HER2 Blockade. Cancer discovery, 2016, Volume: 6, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Humans; Lapatinib; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2016
Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer, 2016, 08-01, Volume: 122, Issue:15 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. PloS one, 2016, Volume: 11, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Italy; Lapatinib; Logistic Models; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Young Adult	2016
Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma. Oncology reports, 2016, Volume: 36, Issue:3 Topics: Animals; Benzodioxoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Quinazolines; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays	2016
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. Clinical lung cancer, 2017, Volume: 18, Issue:1 Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment	2017
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Science translational medicine, 2016, 12-07, Volume: 8, Issue:368 Topics: Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Central Nervous System Neoplasms; Disease Models, Animal; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spinal Cord	2016
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer. Oncotarget, 2017, Jan-24, Volume: 8, Issue:4 Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Movement; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxyprostaglandin Dehydrogenases; MCF-7 Cells; Mice, Inbred BALB C; Mice, SCID; Multidrug Resistance-Associated Proteins; Neoplasm Metastasis; Organic Anion Transporters; Propionates; Quinazolines; Quinolines; Receptors, Prostaglandin E, EP4 Subtype; RNA Interference; Signal Transduction; Time Factors; Transfection; Triple Negative Breast Neoplasms; Tumor Microenvironment; Tyrphostins	2017
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion. Clinical lung cancer, 2017, Volume: 18, Issue:3 Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Circulating Tumor DNA; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Genome; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Neoplasm Metastasis; Oncogene Proteins, Fusion; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; Recurrence	2017
Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. World journal of gastroenterology, 2017, Feb-28, Volume: 23, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Retrospective Studies; Thiophenes; Time Factors; Treatment Outcome	2017
As metastasis yields its biological secrets, researchers hope to apply findings. Journal of the National Cancer Institute, 2008, Aug-06, Volume: 100, Issue:15 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Denosumab; Drug Design; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Quinazolines; RANK Ligand; Receptor, ErbB-2; Trastuzumab	2008
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer. Bulletin of experimental biology and medicine, 2008, Volume: 145, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome	2008
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer, 2009, Feb-01, Volume: 115, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quality of Life; Quinazolines; Sensitivity and Specificity	2009
Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience. Oncology, 2009, Volume: 76, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2009
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. The European respiratory journal, 2009, Volume: 33, Issue:2 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome	2009
Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clinical & experimental metastasis, 2009, Volume: 26, Issue:5 Topics: Animals; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Disease Models, Animal; Ferric Compounds; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A	2009
Lapatinib: new drug. For some women with metastatic breast cancer. Prescrire international, 2009, Volume: 18, Issue:99 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Female; Fluorouracil; France; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines	2009
ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-01, Volume: 15, Issue:11 Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cell Movement; ErbB Receptors; Female; Gefitinib; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays	2009
[Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials]. Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Young Adult	2009
Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 69, Issue:1 Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Insurance, Health, Reimbursement; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results	2010
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Molecular cancer research : MCR, 2009, Volume: 7, Issue:10 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines	2009
Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working? Oncology (Williston Park, N.Y.), 2009, Volume: 23, Issue:11 Suppl N Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Breast Neoplasms; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab	2009
Targeting breast cancer stem cells. Breast (Edinburgh, Scotland), 2009, Volume: 18 Suppl 3 Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Isoenzymes; Lapatinib; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Retinal Dehydrogenase; Signal Transduction	2009
Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clinical & experimental metastasis, 2010, Volume: 27, Issue:1 Topics: Animals; Cell Line, Tumor; Cell Movement; Disease Progression; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Metastasis; Pyrroles; Quinazolines; Receptor, PAR-1; Skin Neoplasms	2010
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib. Clinical lung cancer, 2010, Volume: 11, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2010
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-15, Volume: 16, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Female; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quinazolines; Treatment Outcome	2010
Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Molecular cancer, 2010, Feb-22, Volume: 9 Topics: Aneuploidy; Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Aurora Kinases; Breast Neoplasms; Cell Proliferation; Female; G2 Phase; Humans; Mice; Mitosis; Neoplasm Metastasis; Organophosphates; Polyploidy; Polyubiquitin; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Quinazolines; Tumor Stem Cell Assay; Ubiquitination; Xenograft Model Antitumor Assays	2010
Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3 Topics: Adenocarcinoma; Aged; Diagnosis, Differential; DNA Mutational Analysis; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Pneumonectomy; Quinazolines; Radiography, Thoracic	2010
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy. BMJ (Clinical research ed.), 2010, Jun-11, Volume: 340 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Drug Recalls; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom	2010
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. The European respiratory journal, 2011, Volume: 37, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Biopsy; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome	2011
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer research, 2010, Volume: 30, Issue:7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids	2010
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:2 Topics: Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Green Fluorescent Proteins; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Metastasis; Quinazolines; Recurrence	2010
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer biology & therapy, 2010, Nov-01, Volume: 10, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2010
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer, 2011, Feb-15, Volume: 117, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed	2011
Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Dec-15, Volume: 16, Issue:24 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chromosomes, Human, Pair 17; Female; Gene Amplification; Humans; Lapatinib; Neoplasm Metastasis; Polyploidy; Prognosis; Quinazolines; Receptor, ErbB-2	2010
Recurrent myocardial infarction associated with gefitinib therapy. Journal of thrombosis and thrombolysis, 2011, Volume: 32, Issue:1 Topics: Antineoplastic Agents; Carcinoid Tumor; Gefitinib; Humans; Male; Middle Aged; Myocardial Infarction; Neoplasm Metastasis; Quinazolines	2011
Analysis of tumor burden versus progression-free survival for Phase II decision making. Contemporary clinical trials, 2011, Volume: 32, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden	2011
Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer. The Tokai journal of experimental and clinical medicine, 2010, Dec-20, Volume: 35, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Failure	2010
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC cancer, 2011, Mar-02, Volume: 11 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2011
[Survival-related clinical factors of patients with advanced non-small cell lung cancer after 2000]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Survival Rate	2011
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Cancer, 2011, Nov-01, Volume: 117, Issue:21 Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2011
Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Withholding Treatment	2011
The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor. International journal of oncology, 2011, Volume: 39, Issue:3 Topics: Bone Neoplasms; Cell Line, Tumor; Cell Movement; Humans; MAP Kinase Kinase 4; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Models, Molecular; Molecular Targeted Therapy; Neoplasm Metastasis; Oncogene Protein v-akt; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, IGF Type 1; RNA, Messenger; Signal Transduction	2011
Vandetanib: first global approval. Drugs, 2011, Jul-09, Volume: 71, Issue:10 Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Drug Approval; Drug Design; Humans; Neoplasm Metastasis; Piperidines; Quinazolines; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2	2011
Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Metastasis; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction	2011
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PloS one, 2011, Volume: 6, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Cetuximab; DNA; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Reporter; Green Fluorescent Proteins; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Lapatinib; Molecular Sequence Data; Neoplasm Metastasis; Quinazolines; Transcription, Genetic	2011
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome	2012
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Failure	2012
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Dec-01, Volume: 29, Issue:34 Topics: Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines	2011
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-10, Volume: 30, Issue:2 Topics: Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Thyroid Neoplasms	2012
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clinical & experimental metastasis, 2012, Volume: 29, Issue:3 Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; Protein Kinase Inhibitors; Quinazolines; RANK Ligand	2012
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib]. Pneumologie (Stuttgart, Germany), 2012, Volume: 66, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis	2012
Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma. Die Pharmazie, 2012, Volume: 67, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aging; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Retrospective Studies; Software; Tomography, X-Ray Computed; Treatment Outcome	2012
The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis. Life sciences, 2012, Oct-15, Volume: 91, Issue:13-14 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Matrix Metalloproteinases; Mice; Mice, Nude; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Pyrrolidines; Quinazolines; Receptor, Endothelin A; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction	2012
Targeting nuclear factor-κB suppresses the negative effect of toll-like receptor 4 signaling on antimetastasis therapy based on targeting αvβ3. Cancer science, 2012, Volume: 103, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Female; Fibronectins; Integrin alphaVbeta3; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms, Experimental; NF-kappa B; Quinazolines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Survival Analysis; Toll-Like Receptor 4	2012
Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2012, Volume: 77, Issue:2 Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2012
Cardiotoxin III suppresses MDA-MB-231 cell metastasis through the inhibition of EGF/EGFR-mediated signaling pathway. Toxicon : official journal of the International Society on Toxinology, 2012, Volume: 60, Issue:5 Topics: Analysis of Variance; Blotting, Western; Cell Line, Tumor; Cell Movement; Cobra Cardiotoxin Proteins; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Female; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Neoplasm Metastasis; Phosphorylation; Quinazolines; Signal Transduction; Tyrphostins	2012
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Molecular oncology, 2012, Volume: 6, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Metabolome; Metabolomics; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome	2012
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sulfonamides	2012
Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2 Oncology reports, 2012, Volume: 28, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mouth Neoplasms; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Wound Healing	2012
Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:8 Topics: Animals; Butadienes; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; Female; Focal Adhesion Kinase 1; Humans; Integrin alpha6beta4; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tetraspanin 24; Transendothelial and Transepithelial Migration	2012
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. Journal of medical economics, 2013, Volume: 16, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Health Services; Humans; Lapatinib; Middle Aged; Models, Econometric; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab	2013
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series. Anticancer research, 2012, Volume: 32, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Salvage Therapy; Urinary Bladder Neoplasms; Urologic Neoplasms	2012
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Retrospective Studies	2012
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature. Molecular bioSystems, 2013, Volume: 9, Issue:6 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Profiling; Humans; Mesoderm; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Interaction Maps; Protein Kinases; Proteome; Proteomics; Quinazolines; Sorafenib	2013
CEA fluctuation during a single fluorouracil-based chemotherapy cycle for metastatic colorectal cancer. Anticancer research, 2013, Volume: 33, Issue:1 Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Thiophenes; Tomography, X-Ray Computed	2013
Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma. PloS one, 2012, Volume: 7, Issue:12 Topics: Animals; Anoikis; Antineoplastic Agents; Apoptosis; Carcinoma, Adenoid Cystic; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Salivary Gland Neoplasms; Snail Family Transcription Factors; Transcription Factors	2012
[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate	2012
Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. Clinical lung cancer, 2013, Volume: 14, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Survival Rate; Tumor Burden	2013
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC cancer, 2013, Jan-18, Volume: 13 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; DNA, Viral; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Panitumumab; Proportional Hazards Models; Quinazolines; Retrospective Studies	2013
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Molecular cancer therapeutics, 2003, Volume: 2, Issue:6 Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Liver Neoplasms; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Phosphorylation; Quinazolines; Signal Transduction	2003
Treatment of advanced gastric cancer: where we are in 2003. Onkologie, 2003, Volume: 26, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Thiophenes; Treatment Outcome	2003
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids	2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Aug-01, Volume: 22, Issue:15 Topics: Administration, Oral; Biomarkers; Breast Neoplasms; Endpoint Determination; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Mouth Mucosa; Neoplasm Metastasis; Phosphorylation; Pilot Projects; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin; Tomography, Emission-Computed	2004
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 1 Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Melanoma; Mice; Mice, Inbred BALB C; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Oligonucleotides, Antisense; Phenotype; Piperidines; Placebos; Quinazolines; RNA; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor A	2004
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis, 2004, Volume: 7, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Cell Line, Transformed; Disease Models, Animal; Female; Liver Neoplasms; Mice; Mice, SCID; Microscopy, Video; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Piperidines; Quinazolines	2004
Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. The Journal of biological chemistry, 2005, Apr-29, Volume: 280, Issue:17 Topics: Active Transport, Cell Nucleus; Alkaloids; Annexin A5; Apoptosis; Carcinogens; Cell Line, Tumor; Cell Proliferation; Collagen; Cytokines; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Enzyme Activation; Evodia; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; I-kappa B Kinase; Immunohistochemistry; Immunoprecipitation; In Situ Nick-End Labeling; Indole Alkaloids; Inflammation; Laminin; MAP Kinase Signaling System; Microscopy, Fluorescence; Models, Chemical; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Plant Extracts; Protein Serine-Threonine Kinases; Proteoglycans; Quinazolines; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation	2005
Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 48, Issue:1 Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome	2005
Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. British journal of cancer, 2005, May-09, Volume: 92, Issue:9 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Epidermal Growth Factor; Female; Gefitinib; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Tumor Necrosis Factor-alpha	2005
The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. The Journal of thoracic and cardiovascular surgery, 2005, Volume: 129, Issue:5 Topics: Antineoplastic Agents; Cell Movement; Cell Proliferation; Cocarcinogenesis; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Gene Expression Regulation, Neoplastic; Humans; Laminin; Mesothelioma; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Pleural Neoplasms; Proteoglycans; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A	2005
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thrombosis and haemostasis, 2005, Volume: 93, Issue:5 Topics: Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Chemotaxis; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Laminin; Male; MAP Kinase Signaling System; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Diacylglycerol-Lyase; Phosphoinositide Phospholipase C; Phosphoric Monoester Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteoglycans; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Proteins; Urokinase-Type Plasminogen Activator	2005
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis, 2004, Volume: 7, Issue:4 Topics: Animals; Blood Vessels; Carcinoma, Renal Cell; Cell Division; Enzyme Inhibitors; Humans; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Quinazolines	2004
Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Fundamental & clinical pharmacology, 2005, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Quinazolines	2005
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. International journal of cancer, 2006, Jan-15, Volume: 118, Issue:2 Topics: Biomarkers, Tumor; Carcinoma, Signet Ring Cell; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasms, Experimental; Peritoneal Neoplasms; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Tumor Cells, Cultured	2006
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncology research, 2005, Volume: 15, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion; Quinazolines; Recurrence; Retreatment; Time Factors	2005
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells. Clinical & experimental metastasis, 2005, Volume: 22, Issue:3 Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; In Vitro Techniques; Injections, Subcutaneous; Lung Neoplasms; Male; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Mas; Quinazolines; src-Family Kinases; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2005
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin. Prescrire international, 2005, Volume: 14, Issue:80 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Tegafur; Thiophenes; Treatment Outcome; Uracil	2005
Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. Respirology (Carlton, Vic.), 2006, Volume: 11, Issue:3 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome	2006
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Patient Selection; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Time Factors; Vascular Endothelial Growth Factor A	2006
Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia (New York, N.Y.), 2006, Volume: 8, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Matrix Metalloproteinases, Membrane-Associated; Neoplasm Metastasis; Piperidines; Quinazolines; Quinazolinones; Rats; Rats, Inbred F344	2006
Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model. Oncology reports, 2006, Volume: 16, Issue:1 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines	2006
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Nov-01, Volume: 12, Issue:21 Topics: Adenocarcinoma; Amino Acid Sequence; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; In Situ Hybridization; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction	2006
Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clinical breast cancer, 2006, Volume: 7, Issue:4 Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Infant, Newborn; Lapatinib; Live Birth; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines	2006
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anti-cancer drugs, 2007, Volume: 18, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Quinazolines; Regional Blood Flow; Signal Transduction; Skin; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2	2007
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anti-cancer drugs, 2007, Volume: 18, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography	2007
Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib. International journal of oncology, 2007, Volume: 31, Issue:6 Topics: Adenocarcinoma; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; RNA, Small Interfering; Transfection	2007
Signaling networks assembled by oncogenic EGFR and c-Met. Proceedings of the National Academy of Sciences of the United States of America, 2008, Jan-15, Volume: 105, Issue:2 Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Neoplasm Metastasis; Phosphotyrosine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction	2008
Development of new targeted therapies for breast cancer. Breast cancer (Tokyo, Japan), 2008, Volume: 15, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Female; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Trastuzumab	2008
Erlotinib: new indication. Metastatic cancer of the pancreas: palliative care is still the best option. Prescrire international, 2008, Volume: 17, Issue:93 Topics: Drug Approval; Europe; Humans; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic	2008
Possible relationship between glycosphingolipids and the formation of metastasis in certain human experimental tumors. Journal of the National Cancer Institute, 1980, Volume: 65, Issue:2 Topics: Animals; Carcinoma, Squamous Cell; Chick Embryo; Gangliosides; Glycosphingolipids; Humans; Neoplasm Metastasis; Neoplasms, Experimental; Quinazolines; Sarcoma; Thiazoles	1980
[Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection]. [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 1993, Volume: 68, Issue:5 Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Transplantation; Platelet Aggregation Inhibitors; Quinazolines; Rats; Rats, Inbred Strains	1993
Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. International journal of cancer, 1997, Mar-17, Volume: 70, Issue:6 Topics: Amphiregulin; Antineoplastic Agents; Breast Neoplasms; Cell Division; Collagenases; EGF Family of Proteins; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gelatinases; Glycoproteins; Growth Substances; Humans; Intercellular Signaling Peptides and Proteins; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasm Metastasis; Quinazolines; Tumor Cells, Cultured; Up-Regulation	1997
Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biological & pharmaceutical bulletin, 2001, Volume: 24, Issue:8 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Colonic Neoplasms; Female; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Plant Extracts; Quinazolines; Tumor Cells, Cultured	2001
The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer research, 2002, Feb-15, Volume: 62, Issue:4 Topics: Animals; Cell Movement; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Mice; Neoplasm Metastasis; Quinazolines; ral GTP-Binding Proteins; Tumor Cells, Cultured; Tyrphostins; Urinary Bladder Neoplasms	2002
Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer. Seminars in oncology, 1988, Volume: 15, Issue:2 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Trimetrexate	1988
Clinical pharmacology of trimetrexate. Clinical pharmacology and therapeutics, 1987, Volume: 42, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Quinazolines; Trimetrexate	1987
Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists. Seminars in oncology, 1988, Volume: 15, Issue:2 Suppl 2 Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Resistance; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Quinazolines; Trimetrexate	1988
Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer. Seminars in oncology, 1988, Volume: 15, Issue:2 Suppl 2 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Time Factors; Trimetrexate	1988
Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer. Seminars in oncology, 1988, Volume: 15, Issue:2 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Quinazolines; Trimetrexate	1988
Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Tolerance; Female; Humans; Infusions, Parenteral; Kinetics; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Quinazolines; Solubility	1986